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ABSTRACT
A reduction in microRNA (miR)-133a is associated with dilation of the
thoracic aorta (TA). Since wall tension increases with vessel diameter, this study
tested the hypothesis that elevated mechanical tension induces the loss of miR133a in the TA. Elevated tension (1.5g, 3hrs) applied to murine TA ex vivo reduced
miR-133a (0.31±0.17 vs 1.00±0.25 fold; p<0.05 vs normotension (0.7g)). Cyclic
stretch (12%, 1Hz, 3hrs) reduced miR-133a in TA fibroblasts (0.21±0.02 vs
1.00±0.27 fold; p<0.05 vs static control), with no change in smooth muscle cells.
Neither transcription of miR-133a nor mRNA/protein levels of three microRNAspecific exoribonucleases were altered with stretching of the fibroblasts. However,
stretch induced exosome secretion of miR-133a.

Two in vivo models of

hypertension were utilized to determine the effect of elevated wall tension on miR133a in the TA:

Angiotensin-II infusion (1.44mg/kg/day, 28 days) and a

spontaneous hypertensive mouse line (BPH2). In both models, blood pressures
were elevated and miR-133a was decreased in the TA compared to normotensive
mice (0.69±0.06 and 0.52±0.04 vs 1.00±0.13 fold respectively; p<0.05 for both).
Plasma miR-133a was elevated in the BPH2 mice (3.39±0.77 vs 1.00±0.41 fold;
p<0.05 vs normotensive). Plasma miR-133a was also elevated in hypertensive
human subjects (1.55±0.26 vs 1.00±0.18 fold, p<0.05 vs normotensive). These
findings demonstrate that the reduction in miR-133a levels that occurred with
increased mechanical stretch of the TA was likely driven by exosome secretion
from TA fibroblasts, and may provide a novel target for detrimental remodeling of
the vasculature in the setting of hypertension.

ix

CHAPTER 1: Introduction

The Aorta
The aorta is the largest artery within the body and functions to carry
oxygenated blood from the left ventricle to the systemic circulatory system. The
aorta is separated from the left ventricle by the aortic valve and may be divided
into seven regions: the aortic root, ascending aorta, ascending arch, the vessel
bearing arch, aortic isthmus, descending aorta and abdominal aorta.(1) The
abdominal aorta may be further divided into the paravisceral and infrarenal
segments. The characteristics of each region affect both clinical manifestation of
disease as well as selection of treatment strategies. Embryologically, the
thoracic and abdominal portions of the descending aorta develop from distinct
sources of mesenchymal cells, and regional heterogeneity is becoming
increasingly evident.(2) Conventionally, the aorta has been considered as a
conduit, carrying blood from the heart with uniform cellular and extracellular
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structure and function; however, it is becoming increasingly evident that the aorta
is a highly complex tissue system that is dynamically regulated.
The ability of the aorta to stretch radially is referred to as vessel
compliance, and this property serves to maintain continuous flow of the pulsatile
exiting of blood from the heart. During systole, blood is ejected from the left
ventricle causing the proximal aorta to distend approximately 4%, and during
diastole the aorta will recoil, continuing to propel blood forward toward the
capillary beds.(1, 3) This allows for cardiac output to be delivered steadily
throughout the cardiac cycle.(4) The radial stretch of the aorta caused by the
blood ejected from the aortic valve initiates a pressure wave which is propagated
along the aorta as it moves peripherally. This pressure wave travels much faster
than the blood, at a rate of 4 m/second in the proximal aorta, 6 m/second in the
abdominal aorta and approximately 12 m/second in the peripheral arteries,(5)
and is the pulse that can be detected by palpation.
The velocity of the pressure wave is inversely proportional to the
compliance of the aorta and arterial wall stiffness may be measured noninvasively by the measuring pulse wave velocity.(6) The portion of the aorta that
is proximal to the heart is more compliant than the distal regions, such as, the
abdominal aorta.(7) Aortic compliance reduces the workload of the heart. If
compliance is lost and the vessel wall becomes ridged, pulse pressure rises
dramatically, requiring the heart to pump against a large afterload. With
increased blood pressure, the aorta will become stiffer, as it is already distended.
2

Furthermore, regardless of alterations in pressure, if the aortic wall becomes
more ridged as a result of alterations in vessel composition, this will allow
pressure to reflect back from peripheral vascular system to the heart, while the
aortic valve is still open, increasing the afterload on the heart.(8) Therefore, a
less compliant aorta places more stress on the heart through elevated
myocardial work and a less efficient cardiac ejection.
Aortic wall tension is directly proportional with vessel diameter and wall
thickness. The law of Laplace illustrates the relationship between transmural
pressures pushing outward against the constricting forces of the elastic
components in the aortic wall. This relationship yields wall tension, which is
equal to pressure multiplied by the radius of the vessel then divided by vessel
thickness. Therefore, either an increase in pressure or an increase in aortic
diameter results in elevated wall tension, and loss of aortic compliance.

The Aortic Wall
The human aorta is composed of a trilaminar wall approximately 4mm in
thickness. The three layers are referred to as the intima, media, and adventitia.
Each consists of distinct structural and cellular components that coordinate the
primary function of maintaining aortic compliance. The proper function of the
aortic wall is governed by the ongoing homeostatic balance between deposition
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and degradation of the extracellular matrix (ECM) components in the
microstructure by the endogenous cells within each layer.
The extracellular matrix (ECM) refers to the composite of multiple proteins
that form structures connecting cells within a network. Two major components of
the ECM include collagen and elastin, which comprise a cytoskeleton
surrounding the cells and further contain sequestered growth factors and
cytokines. This high amount of elastic and collagen fibers, allow the vessel to be
distensible and compliant. Fibrillins, a class of microfibers, are closely
associated with elastin, forming elastic lamella.(9) Elastin is a matrix protein
which is composed of nonpolar hydrophobic amino acids, such as, glycine,
alanine, valine, and proline. After being secreted by the endogenous fibroblasts
and smooth muscle cells of the aorta, the elastin molecules remain in a random
coil configuration in the extracellular space. They are covalently cross-linked
between lysine residues and assemble into a highly elastic network of fibers,
capable of stretching more than 100% under physiological conditions.(10)
Fibronectin plays a key role in cellular attachment to the ECM through interaction
with integrins, and has been demonstrated to effect major aspects of cellular
phenotype, such as proliferation and migration.(11) Proteoglycans are also
found in the aortic wall and function to interact with hyaluronic acid, a component
of the ECM which contributes to tissue hydrodynamics, cellular signaling, and
interaction with collagen.(12) Collagens function to provide structural support of
the vessel wall. Much less elastic than elastin, collagen can only be stretched
4

approximately three to four percent under normal physiological conditions. The
basic units of collagen fiber secreted by the endogenous aortic cells are type I
and type III collagen.(13) These are two of the fibrillar collagens that once
secreted assemble into fibrils that aggregate forming collagen fibers.
Compliance of the aorta is largely determined by elastin and collagen content,
two components of the ECM which have gained a significant interest and thus
have been well studied.
The ratio of elastin to collagen is greater in the proximal aorta, and
approximately equivalent in the distal portions.(1) This histologic structure
results in the ability of the proximal aorta to accommodate the stroke volume
delivered by the heart at physiologic pressures. Energy is stored as the aorta
distends, and then is released to passively continue the flow of blood to the
capillaries. These components, as well as the cells that produce and maintain
them, are organized into three distinct layers that coordinate the primary function
of maintaining aortic compliance.
The intima is the thin, innermost layer of the aorta, composed of an
endothelium, a monolayer of simple squamous epithelial cells, fixed to a
connective tissue matrix. In the normal aorta, the endothelial cell layer functions
to regulate diffusion of nutrients and water from the blood, and also to transduce
adrenergic stimulation. Marking the border of the intima is a perforated layer
consisting of an elastic fiber network principally organized in a longitudinal
direction, known as the fenestrated membrane. If exposed to vascular disease
5

risk factors, such as, hypertension, smoking, dyslipidemia or diabetes for
example, the intima is prone to development of atherosclerotic plaques, ulcers,
and thrombi. Interestingly, presence of atherosclerotic lesions may be predicted
by blood flow simulation, identifying that location is related to hemodynamics.(14,
15) At these points, the endothelium is exposed to the influence of low shear
stress, identified as atherogenic, or oscillatory shear stress, which has been
attributed to increased risk for the formation of calcified plaques, a condition
leading to the deposition of calcium salts leading to increased stiffness of the
vessel.(16)
The tunica media comprises the middle layer and is the thickest portion of the
aortic wall. This layer is composed of lamellae sheets of elastic fibrils and
collagen (in humans, approximately 50 in the thoracic and 28 in the abdominal),
smooth muscle cells, fibroblasts, and other extracellular matrix proteins.(17) The
composition and organization of the media give the aorta elastic properties
allowing for distention while providing strength.
The outer most layer of the aortic wall is the adventitia. This layer is a
complex heterogeneous portion of the vessel wall, containing largely collagen
acting as an ECM scaffold with fibroblasts, blood and lymphatic vessels, nerves,
progenitor and immune cells.(18) The adventitia provides metabolic support to
the aorta and functions as a fibroblasts and stem cell progenitor reservoir.(19)
The adventitia allows for these cell types to rapidly migrate into the media in
response to injury. It is these cellular components that interact with the
6

extracellular components of the aortic wall to mediate normal function. The
adventitia has been demonstrated to respond to elevations in wall tension. It has
been described as the principal “injury-sensing tissue” of the vessel wall.(20)
The three endogenous cell types residing in the aortic wall are fibroblasts,
smooth muscle cells, and endothelial cells. Each is capable of altering the
structure of the aorta, contributing to the maintenance of vascular homeostasis.
First, the layer of endothelial cells functions in the regulation of diffusion and
migration of circulating components from the blood and is responsible for signal
transmission and vascular tone. Second, the smooth muscle cells make up the
largest percentage of cells in the healthy aorta and are arranged circumferentially
within the elastic lamellae. The major function of the smooth muscle cells
consists mainly of regulation of medial strength and vessel contraction. Finally,
the fibroblasts are considered the critical cell type functioning to maintain
homeostasis of the aortic wall. The homeostasis-maintaining function is fulfilled
through an outside-in regulation of vascular structure and functions by vascular
adventital fibroblasts in response to stress, injuries, cytokines, and
hormones.(18, 21, 22)

Aortic Aneurysms
Aortic disease in general are a significant source of mortality for the
population, causing as many as 15,000 deaths annually in America, consistently
7

placing aortic disease among the top 20 causes of death. The most recent data
available from the Centers of Disease Control and Prevention (2014) indicate
that aneurysm disease is the 18th most common cause of death in all individuals
and the 15th most common cause of death in individuals older than 65 years of
age, accounting for 13,843 and 11,147 deaths in these 2 groups respectively.(2325) An aortic aneurysm is defined as a localized dilation of the aorta with a
cross-sectional diameter greater than fifty percent larger than the normal range
for a given age and body size. Locations of aortic aneurysms vary. Believed to
be due to regional heterogeneity of the aorta, abdominal aortic aneurysms
(AAAs) occur below the diaphragm and appear to be strongly associated with
atherosclerosis and inflammation.(26) Conversely, thoracic aortic aneurysms
(TAAs) are consequence of degenerative or hypertension associated aortic
remodeling or based on genetic mutations in rare disorders; however the
underlying mechanisms responsible for pathology are unclear.(27)
It is expected that approximately 25 percent of aortic aneurysms occur in
the supradiaphragmatic portion. It has further been estimated that 60 percent of
the thoracic aortic aneurysms involve the aortic root or ascending aorta, 10
percent involve the arch, 40 percent the descending thoracic aorta, and 10
percent involve the thoracoabdominal portion of the aorta.(28) Within the
spectrum of cardiovascular diseases, these thoracic aortic aneurysms (TAAs) are
considered to be of the most dangerous and difficult to treat problems in
cardiothoracic surgery. Thoracic aortic aneurysms are often asymptomatic and
8

results in a weakened aortic wall and can progress to rupture if left untreated.(29)
Etiologies include those of genetic and non-genetic origin. Hereditary disorders
predisposing the aorta to dilation include, presence of a bicuspid aortic valve,
Marfan syndrome, Ehlers-Danlos syndrome. Pathological conditions from an
acquired disorder also affect aortic dilation. For example, hypertension and
atherosclerosis leave the aorta prone to distention and stiffening. This results in
the lack of ability of the aorta to receive the stroke volume, resulting in further
systolic hypertension, and acceleration of the pulse wave velocity. There
remains a paucity in information with regards to the underlying molecular
mechanisms leading to the development of TAA. Further studies in the pathways
leading to the development of TAA are essential and will provide novel, less
invasive therapeutic strategies.

Genetic and Non-genetic factors leading to TAA Formation
Numerous etiologies can contribute to the development of TAA; however,
most commonly idiopathic non-genetic degeneration of the aortic vascular
extracellular matrix occurs. While a number of factors have been identified that
increase the risk of developing an aortic aneurysm, such as, hypertension,
atherosclerosis, smoking, increased age, and the male gender, the molecular
mechanisms involved with theses associations require further understanding.
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Inherited connective tissue disorders have been attributed to a high
incidence of TAA. Marfan syndrome, for example, is one of the major heritable
disorders of connective tissue with a prevalence of between 1 in 5-10,000.(30)
The primary cause of morbidity and mortality in Marfan syndrome relates to the
common development of cardiovascular complications including dilation of the
aortic root leading to the formation of ascending aneurysm and increased
incidence of aortic dissection.(31) Marfan syndrome has been attributed to
multiple identified mutations within the coding sequence of the Fibrillin-1 (FBN1)
gene.(32-34) Fibrillin-1 is exported from cells, where it functions as a key
component of microfibrils in the extracellular matrix. These microfibrils compose
elastic fibers, which provide elasticity to the aorta,(35) and also function to store
latent cytokines and growth factors, such as, the transforming growth factor β
(TGF-β). Motifs within FBN1 interacts with the proteins which target and
sequester latent growth factors to the ECM allowing for their release.(36)
Therefore, it has been suggested that abnormalities in the FBN1 gene may lead
to impaired sequestration of latent TGF-β complexes, making more available for
activation, leading to enhanced signaling.(37, 38)
Other syndromic aortic aneurysms occur in patients with Loeys-Dietz
syndrome, and Ehlers-Danlos syndrome. Loeys-Dietz syndrome is result of a
heterozygous mutation in the transforming growth factor beta receptors 1 and 2
(most commonly TGFBR2).(39) Mutations in the TGF-β receptors are believed
to result in the overall up-regulation of TGF-β signaling. The classical TGF-β
10

signaling pathway has been demonstrated to induce extracellular matrix
deposition and degradation, and this has been described as the predominant
mechanism in Loeys-Dietz aneurysm formation.(40) In Ehlers-Danlos syndrome,
an autosomal dominant mutation in the collagen 3a1 (COL3A1) gene results in
highly fragile vessels, and effected individuals at a high risk of developing
aneurysm.(41)
Non-syndromic aneurysms are also a significant occurrence, and are
divided into two categories: Familial Thoracic Aortic Aneurysms, where more
than one individuals in a family are affected, and sporadic TAAs, where only a
single person in the family is known to have an aneurysm.(42) Increasing
numbers of genetic loci linked to nonsyndromic TAAs are being identified, such
as, individuals with mutations in genes encoding contractile proteins appear to be
susceptible to TAA. Mutations in the smooth muscle cell α-actin (ACTA2) gene,
as well as, the beta-myosin heavy chain (MYH11) were identified in families with
increased incidence of TAA.(43-45) Mutations of the vascular isoforms of actin
and myosin are thought to trigger profound remodeling of the vessel wall followed
by an increase in aortic stiffness and, ultimately, aortic dilation.
Other factors that have been attributed to the formation and progression of
TAA include developmental malformation of the aortic valve. Typically the aortic
valve consists of three leaflets. However, congenitally two of these three leaflets
may become fused throughout development resulting in a bicuspid aortic valve
(BAV) anatomy. This is the most common genetic cardiovascular malformation,
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occurring in approximately 2% of the population.(46) From an etiological
standpoint, the vast majority of BAV patients have an increase in aortic
dimensions and approximately 20% of these individuals have overt TAA, most
commonly in the aortic root, requiring surgical repair.(47-49) While there is a
clear association between the BAV phenotype and the occurrence of TAA, the
nature and extent of this relationship remains unclear.
Nevertheless, patients with genetic TAAs generally present at an earlier
age (56.8 years) than patients with idiopathic TAAs. This is likely due to the
close observation of aortic diameter in these individuals. The diagnosis of
idiopathic TAA typically occurs serendipitously in individuals over the age of 65
(64.3 years on average) undergoing non-related cardiovascular imaging studies
indicated for diagnostic purposes.(50) Normal aortic diameter is determined
based on gender, age, and body size; however, generally speaking the nonremarkable ascending aorta is <2.1 cm/m2 and the descending aorta is <1.6
cm/m2.(51)
Following identification of aortic dilation, it is usually recommended that a
transthoracic echocardiography is performed after six months following the
recognition of increased aortic diameter to ensure the absence of a rapid
evolution of dilation.(52) Echocardiography however, does not allow for
visualization of the entire aorta, therefore, computed tomography (CT) and
magnetic resonance imaging (MRI) are the most widely used imaging
examinations to evaluate the thoracic aorta.(53) This is due to high spatial and
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temporal resolutions, large fields of view, and multiplanar imaging reconstruction
capabilities, allowing for the assessment and calculation of aortic diameter.
Therefore, CT and MRI play an important role not only in the diagnosis of
thoracic aortic aneurysm, but also in the preoperative assessment and follow up
after treatment. Accurate measurement of aortic diameter is vital in monitoring
the progression of TAA. Aortic measurements are made in true short axis
projection acquired from double oblique views, from one blood-wall boundary to
the other. Furthermore, with CT, gating is performed based on ECG analysis to
insure accurate measurement of aortic diameter in accordance with the cardiac
output, particularly in the ascending aorta.(53)
As aortic diameter is tracked over time, medical therapies are initiated until
the risk of rupture outweighs the risk of surgical repair. The aneurysmal thoracic
aorta grows at an average rate of about 0.1 cm per year in the ascending portion
and a bit faster at 0.3 cm per year in the descending portion.(54) An analysis of
aortic diameter and increased risk of complication revealed sharp hinge points at
which aortic rupture or dissection is likely to occur. These hinge points occur at 6
cm in the ascending aorta and 7 cm in the descending aorta.(54) Thus, it is
important to intervene before aortic diameter reaches these dimensions.

The consideration for medical treatment is a result of a balance between
risk and benefit. While the risk of current pharmacotherapies is generally low,
tolerance of therapy may not be seamless. The current aim of medical treatment
13

is to limit the hemodynamic stress imposed on the aortic wall. To lower wall
stress, medical therapy has been directed at the reduction of shear stress on the
aneurysmal segment of the aorta by reducing blood pressure and vessel
contractility. With the understanding that aortic dilation is increased by
intraluminal pressure, both the distention of the aortic wall with cardiac ejection
during systole and blood pressure have been the target of therapies. However, it
is unclear whether the biochemical alterations driving aortic remodeling may be
attenuated through current pharmacologic antihypertensive treatment.

First line therapy for TAA patients is usually blockade of the betaadrenergic receptor. Beta-adrenergic receptors are classified as beta-1, beta-2,
and beta-3 adrenoceptors. These receptors are members of the G-protein
coupled receptor family and consist of seven membrane spanning domains.(55)
The beta-1 receptors of the myocardium, play an important role in the regulation
of cardiac function. Beta-Blockers were initially proposed as medical therapy for
TAAs based on their ability to reduce blood pressure, cardiac contractility, and
shear stress on the aorta.(56) Initially proposed by Wheat and colleagues,
examination of flow in artificial aortas constructed from Tygon tubing coated
internally with rubber cement revealed that a flattened pressure curve, as that
which occurs with the use of beta-blockers, lessened the separation of rubber
cement when a small tear was introduced, and thus demonstrated a reduction in
shear stress.(57) While it is clear beta-blockers do reduce wall stress, the clinical
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benefit in reference to the reduction of aneurysm growth rate and eventual
rupture remains under debate.
The main work cited advocating the use of beta-blockers in the aneurysm
patient was demonstrated in the study of Marfan Patients.(58) In the study
performed by Shores and colleagues, 70 predominantly young patients with
Marfan syndrome were randomized to treatment with or without a beta-blocker,
then followed over time. The main outcome of this study was that with betablocker treatment, aortic root dilation rate was attenuated. Other beneficial
findings were that beta-blocker treatment improved the rates of death, congestive
heart failure, aortic regurgitation, and dissection. Interestingly, other studies
have demonstrated contradictory results. In fact several studies found
contradictory results and demonstrate no benefit of beta-blocker treatment in the
aortic growth rate in pediatric (59) or adult (60, 61) Marfan patients.
Furthermore, no studies to date have been able to confirm demonstrate a
reduction in the rate of aortic dilation in non-Marfan TAA patients, which make up
the majority of individuals suffering from aortic aneurysm. In fact, one study
suggests that beta-blocker therapy does not protect against TAA growth in nonMarfan patients.(62)
While beta-blockers continue to be the leading pharmacotherapy for
patients with TAA, toleration may be low and another strategy is indicated.
Statins were initially proposed as treatment for abdominal aortic aneurysms
based on their lipid-lowering and antioxidative effects, and are an established
15

therapeutic option for patients with TAA. However, no study to date has
demonstrated that statins reduce the rate of thoracic aortic dilation in humans. A
retrospective analysis from the Aortic Institute at Yale-New Haven Hospital of
1,561 patients with TAA indicated that statin therapy was associated with a delay
in time to surgery and complications, including aortic dissection, rupture or
death.(63) While, retrospective analyses suggest a possible therapeutic benefit,
direct proof is lacking.
Nevertheless, current pharmacotherapy available for the treatment of TAA
remains extremely limited, and were derived from studies conducted in select
populations, such as, in patients with Marfan syndrome. In short, even with
current treatment options, the majority of thoracic aortic aneurysms will continue
to increase in diameter over time until the hinge point diameter is reached, and
the risk of rupture outweighs the risk of surgical repair; however, current surgical
options are also limited and include open-chest aneurysm repair or endovascular
intervention.

Surgical Management
The present standard surgical treatment for thoracic aortic aneurysms is
open-chest aneurysm repair. The goal of the open-chest approach is to replace
the weakened, dilated portion of the aorta with a graft. This approach to repair
requires a highly experienced thoracic surgical team and presents the surgeon
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with a multitude of technical and cognitive challenges that extend through the
perioperative and postoperative period. Replacement of the dilated aorta carries
acceptable risk in regard to operative death and postoperative quality of life.(64)
Early reports indicated a perioperative mortality rate ranging between 12% and
44% depending on the extent of comorbidity and urgency of the repair.(65, 66)
However, more recent reports indicate significant improvements in mortality rate
of between 4-9% (67) and an incidence of paraplegia at 3% (68) for descending
thoracic aortic resections of TAAs performed in high-volume aortic centers.
Despite these vast improvements in operative complications and mortality rate,
long-term survival (5-year all-cause mortality) remains poor following open-chest
aneurysm repair and adverse cardiovascular events are more common in these
individuals relative to the general population.(69) Nonetheless, a minimally
invasive approach is appealing, especially in older TAA patients, or individuals
with significant comorbidities rendering them unsuitable candidates for the open
surgical repair.
Endovascular repair of thoracic aneurysms is a novel technology that
allows for a less invasive approach for the treatment of thoracic aortic
aneurysms. This is achieved by transluminal placement of one or more stentgraft devices across the longitudinal extent of the aneurysm. Thoracotomy,
aortic cross-clamping, left-heart bypass, and single-lung ventilation are all
avoided with an endovascular aortic procedure. While prospective randomized
studies comparing open repair and endovascular treatment of descending
17

thoracic aortic disease are limited, it does appear that endovascular stentgrafting decreases early mortality and operative complications associated with
open surgical repair.(70) A multicenter, comparative, phase II, nonrandomized
report on the results of open repair versus stent grafting for the treatment of
descending TAAs yielded promising results. In this study, the Gore TAG thoracic
endograft was evaluated against an open-surgery control cohort of patients with
descending TAAs.(71) Operative mortality and occurrence of paraplegia were
significantly lower in the group receiving the TAG stent when compared with the
open surgical group, 2.1% versus 12% (p<0.001) and 3% versus 14% (p<0.003)
respectively. While perioperative mortality appears to be lower with
endovascular stent grafting, this technique is not without limitations. The 2-year
follow-up in this study was limited; however, it was determined that there was no
difference in 2-year survival between the two groups. In a prospective,
comparative, nonrandomized trial of stent grafting versus open surgery of the
descending thoracic aorta, the rate of operative death was halved with stent
grafting, despite the overall higher-risk population of patients being treated, but
unfortunately, there was similar late survival for both cohorts.(72) In several
more recent studies, it was determined that, while peri-operative mortality is
lower with endovascular stent repair, patients selected for this procedure have
worse long-term (4 year) survival than patients selected for open repair.(73, 74)
The results of these observational studies suggest that higher risk patients are
being offered endovascular stenting, and that some do not benefit based on long18

term survival, highlighting the need for future work to identify candidates who are
less likely to benefit from endovascular stent repair.
Importantly, neither open surgical repair, nor endovascular intervention
address the underlying mechanisms responsible for disease and are only
directed at preventing complications from end stage pathology. Furthermore, the
current pharmacotherapy utilized for the TAA patient remains limited, and it is
unclear whether the biochemical alterations driving aortic remodeling may be
attenuated through current antihypertensive treatment. Therefore identifying
significant need for further studies directed toward determination of the
underlying mechanisms responsible for pathology. To further understand
mechanisms involved in the development and progression of aneurysm disease,
research efforts have been placed on the development and characterization of
several different animal models.

Animal Models of Aortic Aneurysm
Animal models have become an important pillar for examining mechanisms
that contribute to the development and progression of human disease, and the
study of aortic aneurysm is certainly no exception. Accordingly, several methods
are commonly utilized to study aneurysm development, primarily in rodents.(75,
76) The three methods routinely used in mice and rats include, intraluminal
elastase perfusion,(77, 78) infusion of angiotensin II (AngII),(79, 80) and
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application of periadventitial calcium chloride.(81, 82) It must be recognized, that
no singular animal model perfectly replicates human aneurysm on a temporal and
molecular scale; however, each of these methods, initiate abnormal remodeling of
the vascular ECM resulting in vessel weakening, loss of compliance, and
increased diameter.

Intraluminal Elastase Perfusion

The intraluminal elastase perfusion model of aneurysm induction was
developed in 1990 by Anidjar and colleagues for the specific purpose of induction
of aneurysm in the abdominal portion of the rat aorta.(77) Since then, these
methods have been successfully applied to the abdominal aorta of mice.(78, 83)
This method includes, exposing the abdominal aorta via laparotomy, then
dissecting the inferior vena cava free from the aorta and ligating the collateral
arteries. This is followed by insertion of a catheter into the femoral artery and
advancing it until the tip is visually confirmed via microscopy to have reached the
infrarenal abdominal aorta. The aorta is then clamped at the level of the left renal
artery and ligated distally around the inserted catheter. A balloon catheter is then
inflated and the vessel is mechanically expanded as the aorta is perfused with
porcine elastase under supra-physiologic pressures for a desired amount of time.
This method, while relatively straightforward in the abdomen, requires
circumferential access to the vessel and temporary vessel occlusion.
Reproducible dilation is achieved immediately following the procedure, and
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progresses rapidly over a relatively short period of time (>100% dilation in 2
weeks).(78) While efficient in the abdominal aorta, this method would be extremely
difficult to perform in the thoracic portion of the aorta due to the anatomy of the
vessel. Since development of this model, application of periadventitial porcine
pancreatic elastase has been attempted.(61) This model results in a rapid dilation
of the abdominal aorta, or approximatly 82% from baseline measurments in two
weeks. While highly reproducible, and less invasive as the infusion model, the
rapid vessel wall injury and progression of dilation limits the ability to study the
initiation and progression phase of aortic aneurysm. It is believed these models
applied to the thoracic portion of the aorta would cause excessive mortality and/or
paralysis and therefore, is more suited for the study of abdominal aortic
aneurysms.

Angiotensin II Infusion

Angiotensin II (AngII) has been shown to have a number of biological effects
on the cardiovascular system.

Effects of AngII include, increased peripheral

vascular resistance through vasoconstriction leading to elevated vascular wall
tension,(84) vascular hypertrophy, cellular proliferation, production of extracellular
matrix, and inflammation in the vessel wall.(85) Increased plasma levels have
been implicated in human atherogenesis (86) and studies in murine models have
demonstrated that prolonged infusion of AngII increases the development of
atherosclerotic lesions in hypercholesterolemic mice driven by macrophage
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infiltration leading to the formation of aortic aneurysm.(79, 87) This model is
achieved in a relatively non-invasive manner through the implantation of an
osmotic pup which delivers AngII over a 4 week period. When AngII is delivered
to the apolipoprotein E knock out mouse, abdominal aortic aneurysm (87) and
ascending aortic aneurysm(88) is induced, and in the low density lipoprotein knock
out mouse, induction of abdominal aortic aneurysm occurs(79). While this method
of aneurysm induction is relatively straightforward and highly reproducible when
performed in the hypercholesteolemic mouse, the occurrence of aneurysm in wild
type C57BL/6 mice is significantly diminished (<50% of that in the low density
lipoprotein knock-out mouse).(89, 90) Therefore, the use of this model becomes
limited due to the requirement of specific transgenic strains.

Periadventitial Calcium Chloride Exposure

First introduced in 1988, Gertz and colleagues developed methodology to
induce progressive aneurysmal dilation accompanied with disruption of the elastic
network within the media of the rabbit common carotid artery.(91) This process
involved bathing the periadventitial surface of the vessel with 0.5 Molar calcium
chloride for fifteen minutes. Advantages of this model include the ability to apply
this procedure to any mouse strain without consideration to genetic background or
lipid status, such as with the AngII infusion model.(92) Subsequently, this model
was applied to the rabbit abdominal aorta,(93) then in 2001, Chiou et al. adapted
this procedure to be performed in the murine abdominal aorta.(81)
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In the

abdomen, it was described that aneurysm development was result of the disruption
of the elastic network within the media accompanied by calcium precipitations and
an increase in inflammatory cell infiltration associated with progressive dilation.
While this model was proven to be highly reproducible and efficient in the
abdominal aorta, these studies do not address aneurysm specifically in the
thoracic aorta. Evidence was accumulating that embryologically, the thoracic and
abdominal portions of the aorta develop from regionally distinct rests of
mesenchymal cells.(2) With the understanding that the cellular biology is different
in these regions, it was inferred that the cause of aneurysm in the thoracic portion
may be distinct as well. Therefore, to define the mechanisms involved in thoracic
aneurysm formation, Ikonomidis and colleagues sought to adapt this method by
selectively exposing the murine descending thoracic aorta to calcium chloride.(82)
For this approach, following intubation and mechanical ventilation, a left-side
thoracotomy is made between the 4th and 5th intercostal space, and the lung is
carefully packed away. The descending thoracic aorta is exposed and diameter is
obtained by calibrated video microscopy. A sponge soaked with 0.5 Molar calcium
chloride is then applied directly to the periadventitial surface and kept in place for
15 minutes. The animal is then recovered and followed over time.
This method results in the reproducible dilation of the exposed portion of
the thoracic aorta reaching maximal diameter of approximately 72% over baseline
measurements at 16 weeks. Similarly to what was observed by Basalyga, the
elastic lamellae thin and flatten as the aneurysm progresses. While the inciting
stimulus of TAA formation remains undefined, it has become clear that TAA is not
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the result of an acute chemical injury, but a process that is initiated and slowly
progresses over time. Early examination of aortic tissue sections two weeks
following calcium chloride exposure revealed normal wall structure and the
absence of inflammatory infiltrate.

Specifically, TAA tissue stained for

macrophages, neutrophils, T-cells, and B-cells revealed little change from
untreated control aortic sections.(94) This murine model of TAA has been proven
to not only recapitulate the structural hallmarks of human TAA, but also the
changes in cellular content, the modifications in biochemical mediators, and the
altered intracellular signaling consistent with what is observed in clinical
specimens, thereby allowing for the elevated potential to identify therapeutic
targets that could influence aneurysm progression.

Alterations in the cellular composition of the aortic wall with the
development of thoracic aortic aneurysm
Through studies of human tissue and animal models of aneurysm, we
have only begun to unravel the complex underlying pathophysiology. In an early
study performed by Jones and colleagues, it was demonstrated that the resident
endogenous cellular population changes throughout the development of
TAA.(94) Using the periadventitial calcium chloride exposure method, aneurysm
was induced in the descending portion of the murine thoracic aorta and tracked
over time. Following tissue harvest at various time points, histological analysis of
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cell-type specific markers was performed, and four marker proteins were utilized
to define the independent cellular populations.
In this study, fibroblasts were identified using an antibody specific for the
collagen receptor, DDR2, which has been shown to be highly specific and display
fibroblast restricted expression in cardiovascular tissue.(95) Smooth muscle
cells were identified using antibodies targeting the intermediate filament protein,
desmin, which has been demonstrated to be found specifically in muscle-derived
cells, including smooth muscle cells.(96-98) To further define the SMC
population, antibodies against α-Smooth muscle actin (αSMA) and the smooth
muscle myosin heavy chain (MYH11) were used. The interesting results of this
study revealed an increase in DDR2 positive cells at 8 and 16 weeks following
the induction of TAA, suggesting an increase in fibroblasts or fibroblast derived
cells. This occurred concomitantly with an increase in MYH11 positive cells,
while αSMA remained unchanged throughout the 16 week time course.
Combined with the observation that the number of desmin positive cells peaked
at 4 weeks, then drastically decreased, this would suggest that as TAA
progresses the number of smooth muscle cells decline, while the emergence of a
synthetic fibroblast-like cellular population occurs. To confirm loss of SMCs,
Jones and colleagues stained serial tissue sections for desmin and active
Caspase-3, which is activated in the apoptotic cell by both extrinsic and intrinsic
cell death pathways.(99) The results demonstrated significant overlap with
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Caspse-3 staining and desmin positive cells at 8 and 16 weeks following TAA
induction, confirming apoptotic loss of specifically SMCs.
Interestingly, this previous study failed to identify the presence or
accumulation of monocytes or macrophages in the aortic media with the
progression of TAA, a characteristic finding in AAA. Using the periadventitial
calcium chloride application method in the murine abdominal aorta, Xiong et al.
demonstrated that AAA formation is highly dependent on monocyte/macrophage
infiltration in the aortic media.(100) These conflicting observations suggest that
exposure of the thoracic aorta to calcium chloride initiates aortic dilation via
different mechanisms as to what occurs in abdominal aneurysm formation,
highlighting the differences in regional heterogeneity of the aorta.
In agreement with many other studies, it has become well described that
in both mouse models and clinical specimens, an apoptotic loss of smooth
muscle cells occurs with aneurysm development.(101) One theory put forth has
suggested that reactive oxygen species (ROS) may play a role in this process.
Increased ROS formation can be stimulated by mechanical stress,(102) and has
been implicated in both AAA,(103) and TAA,(104) and results in elevated ROS
production by smooth muscle cells.(105) It has been demonstrated that ROS are
involved in both degradation of the ECM (106) and also trigger the apoptotic loss
of smooth muscle cells of the thoracic aortic wall in vivo.(107) Moreover, when
ROS production was inhibited in murine knockout models, a reduction in AAA
and TAA formation was observed, strongly suggesting that ROS and the
26

apoptotic loss of smooth muscle cells are important factors leading to the
development of aneurysm.(108, 109)
The emergence of a cellular population displaying DDR2/MYH11/αSMA
positive staining is consistent with that of an activated and synthetic phenotype,
meaning these fibroblasts possess properties of both SMCs and fibroblasts. A
fibroblast derived cell type possessing characteristics of both the secretory
properties of fibroblasts and the contractile properties of smooth muscle cells
constitutes a unique cell type, termed myofibroblast. Studies have demonstrated
that following injury, fibroblasts differentiate into myofibroblasts and play a
significant role in the tissue injury response.(110, 111) It is thought that the
myofibroblasts contribute to tissue repair during normal wound healing; however,
their presence can lead to severe impairment of tissue function when contraction
and ECM protein secretion becomes excessive.(111, 112)
Interestingly, it has been demonstrated that mechanical tension alone can
directly stimulate the differentiation of fibroblasts into this activated synthetic
myofibroblast phenotype.(113) Kessler and colleagues demonstrated that
fibroblasts seeded into a collagen lattice that was mechanically stretched,
allowed for fibroblasts to take on a similar myofibroblast phenotype.(113) The
presence of activated fibroblasts has been well documented in a variety of
pathologies(114), and has also been attributed to a significant role in the tissue
injury response, where these fibroblasts migrate toward the site of injury and
produce critical matrix proteins.(110, 111)
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While cell type identification remains a challenge, particularly for
fibroblasts and smooth muscle cells, Jones et al. were able to identify the
emergence of an activated synthetic fibroblast, with a decline in smooth muscle
cells.(94) While it remained to be determined whether this population of
activated fibroblasts was induced secondary to aortic dilation, or its presence
exacerbated pathological remodeling, it was clear that the synthetic fibroblasts
became the predominant cell type within the aortic wall with aneurysm and
strongly suggests that this population may be managing the process of aortic
dilation.
To support this notion, Jones and colleagues further demonstrated that
associated with this alteration in cellular constituents, aneurysm development
was accompanied with structural changes within the aortic wall.(94) An analysis
of medial elastin content and architecture was performed by histological staining
of aortic tissue sections following the induction of TAA. This analysis, in
agreement with previous work,(115) identified flattening and thinning of the
elastic lamellae at the early stages of aneurysm development progressing to a
decrease in the number of elastic lamellae from six in the control sections to four
at 8 weeks following induction. This reduction in integrity of the elastic lamellae is
a common feature of advanced aortic remodeling as seen in clinical TAA
specimens undergoing vascular remodeling, and likely allows for aortic
dilation.(101, 116, 117) Therefore, it became apparent that rather than a simple
degenerative course, aneurysm development is a dynamic remodeling process
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managed by the cellular population within the aortic wall as a result of adverse
remodeling of the vascular extracellular matrix.

Extracellular matrix remodeling and release of harbored cytokines
While multiple factors contribute to the development of aortic aneurysm, a
hallmark of TAA is abnormal remodeling of the vascular extracellular matrix
(ECM). This process results in vessel weakening and loss of compliance that
allows for progressive dilation and eventual rupture if left untreated. Vascular
remodeling may be defined as any lasting change in the size and/or composition
of an adult blood vessel. It is becoming apparent that remodeling within the
aortic wall results in not only excessive deposition of matrix proteins, but also
significant degradation of critical ECM components. This dynamic process
thereby alters the mechanical strength and integrity of the aorta allowing for
progressive dilation, and furthermore, results in the release of harbored growth
factors and cytokines, progressing pathology by altering phenotype of the
endogenous cellular population.
Importantly, the ECM is no longer thought to be a passive structural
support, but rather a dynamic regulator of growth factor bioavailability.(118) For
example, the ECM serves to sequester and concentrate transforming growth
factor-β (TGF-β), a soluble cytokine secreted into the extracellular space by
endogenous cells. This particular cytokine is a critical growth factor known to
29

effect multiple phenotypic characteristics, such as cellular proliferation, migration,
differentiation, and apoptosis.
This multifaceted cytokine is stored in the ECM within a large latent
complex (LLC), which is composed of a homodimer of mature TGF-β peptide, a
homodimer of an inactive cleaved peptide fragment of TGF-β (the latent
associated protein, LAP), and latent transforming growth factor binding protein
(LTBP1).(36) Sequestered TGF-β is released in its mature form by several
mechanisms, including by direct proteolysis of the ECM,(119) allowing for
interaction with cell surface receptors. This process allows for the induction of
signaling cascades whereby complex cellular pathways may be activated.
Best known for its role in stimulating collagen production and deposition,
(120) dysregulated TGF-β signaling has been implicated in multiple vascular
pathologies, including, atherosclerosis,(121) pulmonary hypertension,(122) and
thoracic aortic aneurysms.(123) TGF-β signaling is highly complex, involving
multiple different functional ligand subtypes, receptor types and subtypes, and
downstream signaling. To simplify, the classical TGF-β pro-fibrotic signaling
pathway is initiated with ligand binding to the type II TGF-β receptor (TGF-βRII),
which is autophosphorylated, then recruits the type I TGF-β receptor (TGF-βRI).
Upon transphosphorylation of the TGF-βRI, a common receptor-SMAD is
activated. The SMADs make up a class of intracellular proteins which function to
transduce extracellular signaling from the TGF-β ligands to the nucleus. Once
activated, the receptor SMAD then binds a co-SMAD (SMAD 2/3) and
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translocates into the nucleus, where it further interacts with transcriptional cofactors and forms an activated transcriptional complex, inducing a pro-fibrotic
profile of gene expression that favors matrix deposition.(124) For example,
critical pro-fibrotic genes induced in response to TGF-β are connective tissue
growth factor (CTGF) (125, 126) and collagen type 1 (COL1a1)(127), which are
known to play significant roles in extracellular matrix remodeling and alteration of
cellular phenotype.
In addition to TGF-βRI, a second type 1 TGF-β receptor has been
identified. The actavin-receptor-like kinase 1 (ALK-1) which interacts with TGF-β
and plays an alternative role activating transcription of a different set of genes.
Like TGF-βRI, ALK-1 is capable of interacting with TGF-βRII in response to TGFβ ligand binding.(128, 129) While activation of TGF-βRI phosphorylates SMAD
2/3, activation of ALK-1 results in SMAD 1/5/8 phosphorylation.(130, 131)
Interestingly, ALK-1 mediated gene expression profiles often occur in opposition
to TGF-βR1 responses, and furthermore has been identified to be an
antagonistic mediator of TGF-βRI signaling.(132, 133) Nevertheless, it has been
proposed that activation of ALK-1 may induce angiogenic factors that contribute
to significant degradation of the vascular ECM.(123)
Interestingly, paradoxical discoveries were made by Jones and
colleagues.(134) Following induction of TAA with the use of the periadventitial
calcium chloride murine model, it was demonstrating that a reduction in the TGFβ receptor 1 occurs, with a concomitant increase in TGF-βRII, while ALK-1
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remained unchanged throughout the progression of TAA.(134) Importantly,
Jones et al. identified that with progression of TAA, SMAD 2/3 signaling may give
way to increased SMAD 1/5/8 signaling altering the cellular response to TGF-β
stimulation throughout TAA development, thus representing a significant change
in signaling outcome. These findings suggest that TGF-β signaling shifts from
matrix deposition in early aneurysm formation, to matrix degradation in later
stage aneurysm progression.
In addition to regulation of fibrotic/degradative gene expression profiles,
TGF-β has been implicated in the induction of SMC apoptosis, and modulation of
fibroblast phenotype. Demonstrated in abdominal aortic aneurysms, Fukui et al.
determined that high levels of TGF-β co-localized with markers specific for SMCs
undergoing apoptosis, demonstrated by TUNEL assay, an identifying marker for
DNA fragmentation.(135) In agreement with previous findings, identifying SMC
apoptosis with the development of TAA in a murine model,(94) these data
suggest that SMC apoptosis may be mediated in part by TGF-β, leaving the
fibroblast population as the predominant cell type to manage the vascular
remodeling process. Also demonstrated by Jones et al. the adventitial fibroblasts
themselves under go phenotypic alterations in TAA by taking on synthetic
characteristics,(94) and it has been proposed that TGF-β may play a significant
role in this differentiation process.(136-138) Taken together, these data indicate
that TGF-β is involved in the induction of SMC apoptosis and alteration of

32

fibroblast phenotype, both of which promote development and progression of
TAA.
It is apparent that TGF-β signaling can regulate the production of critical
vascular matrix proteins as well as matrix degrading enzymes, and suggests that
alterations in signaling may be detrimental to normal vascular function and
architecture. Therefore, further studies directed at targeting TGF-β were initiated
with the goal of attenuation of aneurysm progression. Losartan, an Angiotensin I
receptor blocker seems to exert beneficial effects through inhibiting TGF-β,
thereby reducing matrix degradation in a Marfan syndrome mouse model.(38) In
a murine model of Marfan crossed with an apolipoprotein E-deficient mouse line,
in which angiotensin II is infused to induce aneurysm, losartan prevented
aneurysm formation.(38, 139) However, clinical trials on the effects of losartan
on aneurysm growth rates yielded interesting results. In Marfan syndrome
patients treated with losartan, rate of aortic root dilation was significantly
attenuated following three years of treatment. Conversely, aneurysm
progression beyond the aortic root was not affected by losartan.(140)
Furthermore, the efficacy of losartan on aortic dilation in non-Marfan patients
remains to be determined. To confound these reports, a recent finding published
by Lareyre et al. demonstrated that systemic inhibition of TGF-β exacerbates
sustained aneurysmal dilation in an elastase induced murine model of abdominal
aortic aneurysm.(141)
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Alterations in TGF-β signaling are undisputedly associated with vascular
remodeling and have been directly implicated in aortic aneurysm development.
While, each cell type reacts differently to TGF-β stimulation, it is likely that the
homeostatic balance governing ECM integrity are managed through differential
cellular responses, including newly acquired cellular functions, such as,
degradation of major components within the aortic wall. This process alters the
mechanical strength and integrity of the aorta, thus increasing the potential for
vessel dilation, and therefore increasing wall tension, as tension is directly
dependent on vessel diameter (law of Laplace). Nevertheless, the many roles
TGF-β signaling plays in this process highlight the need for further investigation
in the upstream regulatory mechanisms of these processes.

The role of Matrix Metalloproteinases in vascular ECM remodeling
Both intracellular and extracellular mechanisms function to balance matrix
deposition and degradation in order to maintain structural integrity of the aortic
wall. In the aneurysmal aorta, this balance becomes disrupted in favor of
enhanced proteolysis resulting in the pathological remodeling of the vascular
ECM leading to progressive dilation. As, the aortic ECM provides structural and
biochemical support to the resident cells, remodeling is an important process in
which a critical family of proteolytic enzymes, the matrix metalloproteinases
(MMPs), actively participate through the degradation of all ECM components and
34

subsequent release of sequestered growth factors and cytokines.(123, 142) This
breakdown of normally long lasting matrix molecules, such as elastin and
collagen, has placed a great deal of emphasis on research focusing on the
involvement of MMPs in the ECM remodeling associated with aortic aneurysm
formation and progression.
Interestingly, the first MMP described was discovered by placing a slice of
tail from a tadpole undergoing metamorphosis on a collagen gel, This resulted in
a clearing of a zone surrounding the tissue section, indicating collagenase
activity, and emphasized a key role these enzymes play in the degradation of
ECM molecules.(143) Since this initial discovery, the MMPs have become a
growing class of proteolytic enzymes, with over 24 different sub-types
described.(144, 145)
The MMPs are either secreted from cells, or anchored to the plasma
membrane, and classification has been divided into six groups based on
substrate specificity, sequence similarity, and domain organization. The
collagenases are a group of MMPs with the ability to hydrolyze interstitial
collagens I, II, and III at a specific site, and also retain the ability to digest a
number of other ECM and non-ECM molecules. The gelatinases consist of
gelatinase A and B, MMP-2 and MMP-9 respectively. This group of proteolytic
enzymes has three repeats of a type II fibronectin domain inserted into the
catalytic domain, allowing for binding, and subsequent hydrolysis, to gelatin,
collagens, and laminin.(146) The stromelysins consist of two members with
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similar substrate specificity. In addition to digestion of ECM components,
stromelysin 1 (MMP-3) is capable of activating a number of other MMPs, through
cleavage of the pro-domain, thereby exposing the catalytic domain.(147) The
matrilysins are characterized by the lack of a hemopexin domain, and have the
ability to degrade a number of ECM components. The membrane type MMPs
(MT-MMPs) are a unique class of membrane bound proteolytic enzymes. These
six members are anchored in the plasma membrane of cells and are capable of
degrading all ECM components, releasing latent ECM bound cytokines and
growth factors, and activating latent MMPs. The remainder of the MMPs not
listed above constitute their own class of other MMPs.
Considering the capability of hydrolyzing all components of the vascular
ECM, the physiological activity of MMPs must be tightly regulated to maintain
tissue homeostasis. Indeed, in normal non-pathological tissues, levels of MMPs
are very low.(148) The regulation of MMP activity is controlled at multiple levels.
First, like most messenger RNAs, MMPs are transcribed from DNA by an RNA
polymerase-II-dependent process.(149) Cytokines, hormones, and growth
factors, may increase MMP expression, in most cases by induction of
transcription and increased promoter activity.(150) Second, translation of MMPs
may be regulated in multiple ways. The corresponding mechanisms are primarily
targeted to the control of ribosome recruitment on the initiation codon, but can
also involve modulation of the elongation or termination of protein synthesis by
rapid degradation of the messenger RNA sequence.(151) In most cases,
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translational regulation involves specific RNA silencing proteins to be recruited to
the messenger RNA sequence, a process regulated by microRNAs.(152, 153)
MicroRNAs are small non-coding RNAs which direct the RNA induced silencing
complex to targeted sequences within the messenger RNA transcript, inducing
degradation or, more commonly, translational repression.(154) Third, MMPs are
expressed as inactive zymogens and require proteolytic processing to expose
the active catalytic site. While most MMPs require extracellular activation, few
are activated intracellularly by a mechanism requiring the endoprotease,
furin.(155) This physiological activation occurs in multiple steps. Initially,
activating factors, such as, plasmin and other MMPs disrupt the cytosine-zinc
interaction resulting in a partially active intermediate. For full activation, this
intermediate form requires removal of the pro-peptide region, normally achieved
by further proteolytic processing by other MMPs.(156) Finally, the activity of
MMPs may be regulated by the endogenous tissue inhibitors of matrix
metalloproteinases (TIMPs).
The tissue inhibitors of matrix metalloproteinases (TIMPs) are specific
inhibitors that bind MMPs in a 1:1 stoichiometry.(157, 158) Four TIMPs have
been identified in vertebrates, and expression is tightly regulated during
development and during no-pathological tissue remodeling.(148) While the
TIMPs have been described to be equipotent, their capacity to bind to the MMPs
differ. The conserved region of the N-terminal region of the TIMP binds to the
catalytically active site of MMPs.(159) In addition to inhibition of the MMPs, it
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has become clear that the TIMPs possess other essential biological functions.
Under certain conditions the TIMPs may act as inhibitors of proliferation or
migration,(160) while also possessing growth factor properties thereby
stimulating migration and even apoptosis.(161) In ECM remodeling, as seen in
aortic aneurysms, imbalances in the MMP:TIMP ratio within the aortic wall are
observed, which favor net proteolysis.(162)
In a study designed to demonstrate the ability MMP inhibition by the
TIMPS, adenoviral transfection of human saphenous vein organ culture with
TIMP-1 and TIMP-2 was shown to inhibit MMP-2 and MMP-9 gelatinogenic
activity and reduce neointimal thickening without altering the protein abundance
of either MMP-2 or MMP-9.(163, 164) Furthermore, Allaire and colleagues
demonstrated that overexpression of TIMP-1 by local gene delivery, inhibited
aneurysmal dilation in a rat xenograph model of abdominal aortic aneurysm.(165)
The significance of these findings were two fold. First, this data provides support
to the notion that excessive MMP activity in the vessel wall is an important
contributor to aneurysmal degeneration. Second, inhibition of MMP activity is
sufficient in attenuating aortic dilatation. However, the clinical applicability of
local TIMP gene transfer to the aortic wall, especially within the thoracic portion,
requires significant development before becoming a plausible therapeutic
approach.
A loss in control of MMP activity results in pathological vascular
remodeling and promotes aortic pathology by proteolytic degradation of the
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elastic lamina. Furthermore, increased MMP activity has been reported in
various inflammatory, malignant, and degenerative disorders and leads to
degradation of the ECM.(166) The ECM provides both structural and
biochemical support to the resident aortic cells. When exposed to elevated wall
tension, the adventitial layer begins early and dramatic remodeling,(167) and this
disruption of vascular ECM occurs in part through activation of the MMPs and
results in alterations in the content of collagen and elastin within the cytoskeleton
surrounding the cells.(168)
Increased expression of multiple MMPs have been observed in aortic
aneurysm tissue; however, the prominent degradation of elastin focused much
work on the investigation of MMPs with elastolytic capabilities. Thus, many
studies in both human specimens and animal models have identified that the
gelatinase subclass (MMP-2 and MMP-9), display elevated production and
activity in both abdominal and thoracic aortic aneurysm disease, suggesting
these enzymes may play a significant role in aneurysm development.(92, 93,
169, 170) Moreover, Longo and colleagues demonstrated that macrophage
derived MMP-9 was found to work in concert with mesenchymal cell derived
MMP-2 to induce abdominal aortic dilation.(92) Interestingly, utilizing the calcium
chloride aneurysm induction method, Ikonomidis and colleagues demonstrated in
the thoracic aorta that elevated MMP-9 localized to cells of mesenchymal origin
in the absence of inflammatory infiltrate and that TAA development was
attenuated in mice devoid of the MMP-9 gene.(169) These data demonstrate
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that both MMP-2 and MMP-9 appear to play a significant role in aortic aneurysm
development and furthermore support the notion that there are inherent
differences between the thoracic and abdominal aorta that contribute to the
mechanisms driving aneurysm development. While significant, these findings do
not preclude an important role of other MMPs, serine or cysteine proteases in the
development of aortic aneurysm.
Interestingly, inhibition of angiotensin-converting enzyme has been shown
to both stimulate and inhibit MMPs and the degradation of extracellular matrix in
aortic aneurysms induced in a spontaneously hypertensive rat model.(171)
Thus, the effects of angiotensin-converting enzyme (ACE) inhibitors on aortic
aneurysm has been examined. Due to the contradictory role in MMP activation
and inhibition, it is of little surprise that clinical studies on angiotensin-converting
enzyme inhibitors have reported conflicting findings. One study demonstrates
that patients who received ACE inhibitors were significantly less likely to present
with a ruptured abdominal aortic aneurysm,(172) whereas the results of another
study show that patients taking ACE inhibitors have a faster aneurysm growth
rate.(173)
Doxycycline, a tetracycline-class antibiotic, has been demonstrated to
have an inhibitory effect on a broad spectrum of MMPs. Doxycycline binds the
zinc-containing active site of MMPs and non-selectively inhibits activity.(174) In
several early human studies of small abdominal aortic aneurysms, doxycycline
treatment was suggested to be useful in suppressing MMP 2 and 9 activity.(17540

177) Therefore, it was postulated that doxycycline may affect aneurysm
progression through preventing elastic fiber degeneration. However, a larger
phase II multicenter study was unable to determine a clear effect of doxycycline
treatment on the rate and extent of small abdominal aneurysm expansion.(178)
Efficacy of doxycycline use for the attenuation of TAA was supported in an
animal study of the FBN1 mutation mouse model of Marfan syndrome. Here it
was demonstrated to effect the rate of thoracic aortic dilation.(179) While
promising, demonstration of the efficacy in human TAA with Marfan, as well as
non-Marfan patients, requires additional studies.
Other MMP inhibitors such as o-phenanthroline, batimastat, marimastat,
GM-6001, and PD-166793 have been developed. While these molecules have
demonstrated efficacy in several animal models of pathologies associated with
increased MMP abundance, such as, breast cancer metastasis (180),
atherosclerosis (181), and abdominal aortic aneurysm (182), they have
performed poorly in clinical trials. Due to unanticipated side effects, such as
tendonitis-like fibromyalgia, these trials were halted early, failing to show
expected results.(183, 184) These off target effects highlight the need for
alternative therapeutic strategies targeted toward the regulation of the specific
molecular pathways which are aberrantly activated throughout the development
of aortic aneurysm.
The Membrane Type 1 Matrix Metalloproteinase in aortic aneurysms
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More recently a membrane bound MMP, the membrane type-1 matrix
metalloproteinase (MT1-MMP) has been implicated in aneurysm formation.
Studies examining human and mouse aneurysm specimens from both AAA and
TAA have demonstrated increased abundance of MT1-MMP, suggesting this
enzyme plays an important role in mediating the pathological remodeling
process.(100, 185-188) This class I transmembrane proteolytic enzyme has
gained significant attention due to the several ways by which it may contribute to
aneurysm development. First, MT1-MMP possesses gelatinolytic and
collagenogenolytic activity that can directly degrade the structural ECM.(189)
Second, when on the cell surface, MT1-MMP plays an essential role in the
activation of other MMPs and when internalized, takes on a signaling role. For
example, MMP-2 is secreted into the extracellular space as an inactive
propeptide, there the catalytic portion of MMP-2 is exposed by the removal of the
pro-domain through cleavage mediated by a complex containing MT1-MMP,
TIMP2, and pro-MMP-2.(190, 191) Third, MT1-MMP is known to release ECMsequestered cytokines and growth factors that can further act to drive ECM
remodeling. When MT1-MMP is phosphorylated, it is internalized from the cell
surface, and its role is shifted from MMP-2 activation to intracellular signaling
through the release of theses cytokines and growth factors.(192) Both the latent
TGFβ-binding protein 1 and fibrillin-1a have been identified as substrates for
MT1-MMP.(193, 194) These roles of MT1-MMP identify the multifunctional
contribution toward ECM remodeling and subsequent TAA formation and
progression.
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In a study performed by Jones and colleagues, it was demonstrated that
MT1-MMP expression, abundance and activity is elevated during TAA
development, suggesting a key role in aneurysm disease.(188) In this previous
set of investigations, TAA was induced in murine descending thoracic aortas
using the periadventitial application of calcium chloride. Development of TAA
was tracked over time and aortic dilation was confirmed to be increased when
compared to unoperated control mice. Two weeks following the induction of
TAA, MT1-MMP mRNA levels were increased; however, expression returned to
baseline at subsequent time points. Importantly, MT1-MMP protein remained
unchanged at two weeks post TAA induction, then progressively increased
through the 16 week time course. Combined, these findings identify that
increased protein abundance of MT1-MMP was not simply a result of increased
transcription, but implicate the loss of a posttranscriptional regulatory
mechanism.
Interestingly, in this previous study, it was also identified that MT1-MMP
co-localized to DDR2 positive fibroblasts.(188) In agreement with an earlier
study performed by Jones and colleagues, when aortic fibroblasts from TAA and
control mice were isolated and expanded in culture, it was determined that the
fibroblasts had undergone a significant and sustained alteration in phenotype,
resulting in enhanced proteolytic gene expression, including elevated MT1MMP.(195) Combined, these results further implicate this cell type as a major
mediator of TAA development. Furthermore, Jones and colleagues
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demonstrated a 33% increase in the number of cells staining positive for MT1MMP at 16 weeks following the induction of TAA. (195) However, the observed
70% increase in total MT1-MMP protein abundance observed in 16 week TAA
tissue homogenates suggest that not only is there an increase in the number of
cells producing MT1-MMP, but there is also an increase in the amount of MT1MMP being produced by each cell.
In agreement with the finding that MT1-MMP is elevated during TAA
formation in a murine model, Ikonomidis and colleagues recently demonstrated
elevated MT1-MMP protein abundance in clinical ascending TAA samples.(192)
In this investigation two cohorts of TAA specimens were selected from an aortic
tissue bank, small TAAs (4.0-4.9 cm in diameter), and large TAAs (6.5-8.0 cm in
diameter) and MT1-MMP abundance was compared to aortic tissue harvested
from patients without aneurysm disease. This previous study identified that,
similar to mouse models, MT1-MMP was elevated in both small and large TAAs,
further suggesting that MT1-MMP may indeed play an important role in TAA
formation and progression.
The multiple unique characteristics of MT1-MMP position it at the center of
several mechanisms capable of regulating ECM remodeling; however, less is
understood about the endogenous mechanisms by which this proteolytic enzyme
becomes adversely produced in TAA disease. Thus, studies directed at the
identification of post-transcriptional regulatory mechanisms of MT1-MMP may
provide novel therapeutic strategies for the treatment of TAA.
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MicroRNAs: Regulators of Translation
Increasing evidence supports a direct role for altered microRNA (miR)
abundance in pathological cardiovascular remodeling and disease progression.
The microRNAs constitute an endogenous class of small non-coding RNA
molecules, 20-25 nucleotides in length that have been demonstrated to have
important translational regulatory functions.(196) These small RNA molecules
are used by eukaryotic cells to direct gene silencing.(196) Inside the nucleus,
protein coding genes are transcribed by RNA polymerase II, and following
processing, the messenger RNA is then exported into the cytoplasm. Here
ribosomes catalyze translation of the messenger RNA to form polypeptide chains
that fold into proteins. It is at this point where microRNAs have their gene
silencing effects.
To date, nearly 2000 unique high confidence miRNAs have been identified
in the human genome (mirbase.org). Importantly, it has been well described that
a single miR can target multiple mRNAs, and that a single mRNA can contain
multiple miR binding sites.(197, 198) This suggests that miRs, alone or in
combination, may be able to regulate a coordinated cassette of genes that
together can influence complex cellular functions, such as phenotype.
MicroRNA biogenesis begins from transcription from DNA (overview in
Figure 1.1). Some microRNA sequences are identically repeated in multiple
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locations within the genome, and are differentiated by referring to them as -1 and
-2, and so forth.(199) Like most messenger RNAs, microRNAs are transcribed
from DNA by an RNA polymerase-II-dependent process.(149) However,
microRNA genes are often embedded in introns or exons of other genes.(200)
The transcriptional regulatory elements of microRNAs largely overlap with that of
mRNAs and include, DNA binding factors, promoter structure and histone
modifications.(201, 202) Transcribed is a long primary (pri-) sequence, which
can be over 1,000 nucleotides in length(203), possessing a hairpin structure
where the mature sequence is embedded.(203) Following transcription, the primiR undergoes several steps of maturation. The nuclear ribonuclease (RNase)
Drosha initiates this maturation process by cleaving the stem-loop portion to
release a small hairpin-shaped RNA of approximately 65 nucleotides in length,
called the precursor (pre-) miR.(204) In the precursor miR stemloop structure,
the 5p strand is present in the forward position, while the 3p strand is located in
the reverse position.(199) Following processing by Drosha, the protein, exportin
5 (XPO5) forms a transport complex with a GTP-binding protein and the pre-miR,
allowing for translocation through the nuclear pore complex.(205) Following
nuclear export, the GTP is hydrolyzed resulting in disassembly of the complex
and subsequent release of the pre-miR into the cytosol.(206) Here the pre-miR
is cleaved by RNase III-type endonuclease, Dicer, near the terminal loop, thus
liberating the small RNA duplex.(207) This small RNA duplex is subsequently
loaded onto an Argonaut (AGO) protein, which involves two steps. First, loading
of the RNA duplex, then subsequent unwinding.(208). The two strands of the
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small RNA duplex are cleaved and one strand, known as the passenger strand,
is liberated from AGO, while the remaining strand, known as the guide strand,
remains serving as a recognition sequence for targeted mRNA transcripts.(209)
In the case of the following studies included in this body of work, the guide strand
microRNA being quantified and studied is miR-133a-3p. The passenger strand
either functions merely as a carrier strand and is degraded following ejection
from AGO, or it becomes incorporated in a different AGO complex and functions
as a guide strand itself.(210) Next, the AGO protein containing the guide strand
miR recruits the GW182 protein to form a multimeric effector protein complex
known as the RNA-induced silencing complex (RISC).(211) Silencing of
translation is achieved in two distinct ways: mRNA decay by recruiting
deadenylases and decapping factors, or more commonly translational
repression. Repression may also occur by two mechanisms, one involving
disassociation of the eIF/4E cap, or by recruitment of translational inhibitors
thereby preventing ribosomal loading.(154)
It is widely accepted that miRs are key regulators of complex biological
processes, and it is becoming increasingly apparent that alterations in miR
abundances are associated with multiple cardiovascular diseases. For example,
pathologies including left ventricular hypertrophy, ischaemic heart disease, heart
failure, hypertension, arrhythmias, and more recently aortic aneurysm have all
been associated with abnormal miR levels.(212-218)
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Figure 1.1 MicroRNA Biogenesis
Like all messenger RNA, microRNAs are transcribed from DNA, and this process
is RNA polymerase II dependent and regulated by transcription factors.(1) Transcription
of microRNAs generates a long primary transcript, termed the primary microRNA.(2)
Following transcription, microRNA processing continues with hydrolysis of the transcript
by the enzyme Drosha to produce a precursor microRNA,(3) which then interacts with
Exportin-5 (XPO-5)(4) and is then exported from the nucleus to the cytoplasm (5) where
further hydrolysis by the Dicer Ribonuclease removes the loop portion of the precursor
microRNA (6), generating a double stranded microRNA duplex (7). In the cytoplasm, final
processing occurs as the microRNA duplex interacts with Argonaut (AGO) protein (8) and
is stripped of its complementary passenger strand (9). Incorporation of accessory protein,
GW182, forms the RNA-Induced Silencing Complex (RISC), which can interact with the
3’UTR of target mRNAs (10) resulting in two possible outcomes. Dependent upon the
level of homology between the microRNA and targeted mRNA sequences: if the homology
is high, the targeted mRNA transcript is degraded (11); or if the homology is low, imperfect
base paring between the microRNA and mRNA results in translational repression (12).
The latter outcome occurs in 85% of interactions. In this scenario the RISC Complex
functions by using the incorporated mature microRNA sequence as a target recognition
component. This allows for imperfect interaction with complementary binding sites
predominantly located in the 3’ UTR of a targeted mRNA and results in translational
repression of that particular message.

48

To determine if TAA development coincides with alterations in miRs,
Jones and colleagues performed a microRNA microarrary analysis comparing
the relative abundance of miRs in TAA and non-aneurysm control aortic tissue.
This array identified 37 differentially expressed miRs between normal and TAA
tissue, and furthermore identified 106 miRs that changed from detected to
undetected, or undetected to detected.(212) From this list of differentially
regulated miRs a comprehensive literature search was performed, identifying a
focused set of miRs which appeared to be highly discussed in the cardiovascular
literature. This previous study then confirmed by PCR analysis, that several
microRNAs, including miR-1, -21, -29a, -486, -720, and miR-133a, were reduced
in the ascending aortic tissue from patients with thoracic aortic aneurysm
(TAA).(212) Many of these miRs, including miR-1, -21, 29a, and -133a,
displayed an inverse linear correlation with aortic diameter, such that as diameter
increased, the abundance of miR-133a was reduced.(212)
Upon further review of this set of microRNAs, miR-133a was identified to
directly regulate multiple proteins that are highly involved in both genetic and
idiopathic thoracic aortic aneurysms. Many of the targets of miR-133a play key
roles in determining aspects of cellular phenotype and regulating ECM
remodeling; therefore, finding miR-133a reduced in TAA tissue suggests that the
loss of miR-133a may play an important role in TAA development. First, miR133a targets TGF-β,(219) which is elevated in TAA tissue, induces CTGF
expression, alters fibroblast phenotype and causes apoptosis in smooth muscle
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cells. Second, miR-133a targets TGF-βRII,(219) which is elevated in TAA tissue,
and with the concomitant decline in TGF-βI receptor, shifts TGF-β ligand
signaling to ALK-1, activating the SMAD 1/5/8 pathway, which induces a profile
of gene expression resulting in matrix degradation. Third, miR-133a targets
CTGF,(220) which is elevated in TAA tissue and also alters fibroblast phenotype.
Fourth, miR-133a is known to target the repression of Col1a1.(221) Finally, mir133a targets MT1-MMP,(222) which is elevated in TAA tissue, degrades
components of the ECM, activates other MMPs, such as MMP-2, and directly
releases cytokines such as TGF-β. In addition to the above listed direct targets
of miR-133a, it is apparent that miR-133a may have the capacity to regulate
multiple pathways involved in complex pathology, increasing the significance of
the loss of miR-133a observed in the development of TAA.
The importance of miR-133a in the regulation of extracellular matrix
remodeling in cardiovascular tissue is becoming increasingly recognized. Carè
et al. demonstrated in a murine model of cardiac hypertrophy, that miR-133a is
reduced in the hypertrophied myocardium, and that in vivo knockdown of miR133a (using anti-miR-133a) induced cardiac hypertrophy.(216) Similarly, Torella
et al. demonstrated miR-133a was reduced in the carotid artery following balloon
distension injury in a rat model. Importantly, they demonstrated that systemic
overexpression of miR-133a by adenovirus, attenuated post-injury remodeling, in
contrast to miR-133a knockdown (using an anti-miR-133a oligonucleotide)
enhanced post-injury remodeling.(214) Data from these studies emphasize the
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key role that miR-133a plays in cardiovascular remodeling and suggest that the
loss of miR-133a-mediated translational control of targeted genes likely
contributes to pathologic changes in the extracellular matrix.

While much effort has been directed toward understanding the role of
miRs in modulating cellular targets, less is known about how miR abundance is
regulated within the cell. Accordingly, understanding the mechanisms that
regulate miR-133a cellular abundance is essential, and may provide insight into
potential therapeutic targets.
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SUMMARY
Thoracic aortic aneurysm (TAA) is a localized dilation of the
supradiaphragmatic aorta. This devastating disease process is often
asymptomatic and results in a weakened aortic wall and can progress to rupture
if left untreated;(29) however, the underlying molecular mechanisms leading to
the development of TAA are largely unknown. While there are numerous
etiologies that contribute to the manifestation of TAA, abnormal remodeling of the
aortic extracellular matrix (ECM) and changes in the resident cellular population
universally occur. Histological examination of aortic structure and composition
has demonstrated a decline in the smooth muscle cell population coinciding with
an emergence of fibroblast derived myofibroblasts.(94) It is believed this
population of fibroblasts is managing the remodeling process through the
association with observed elastic fiber and medial degeneration.(63, 94, 168)
Interestingly, it has been demonstrated that isolated primary aortic fibroblasts
from TAA tissue sustain a stable alteration in gene expression profile.(195)
Under normotensive conditions, a physiologically relevant level of wall tension is
essential for maintaining normal vessel structure.(223) According to Laplace’s
law (vessel wall tension = pressure X radius), wall tension is directly related to
the radius of the vessel and intra-arterial pressure, thus, even when blood
pressure is constant and vessel dilation occurs, wall tension rises. Alterations in
the amount of tension placed on fibroblasts have been demonstrated to modulate
complex cellular phenotypes (224-228); however, the regulatory mechanisms
remain unknown. MicroRNAs are powerful regulators of protein abundance and
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cellular phenotypes. Protein translation is regulated by microRNAs through
interaction with the 3’-untranslated region of targeted mRNAs.(229) Importantly,
it has been well described that a single miR can target multiple mRNAs, and that
a single mRNA can contain multiple miR binding sites.(197, 198) Alterations in
microRNA abundance have been associated with a multitude of
pathologies.(230, 231) Previous results from this laboratory determined in clinical
specimens: miR-133a displays an inverse relationship with aortic diameter. As
the aorta dilates, the abundance of miR-133a decreases.(212) The importance of
miR-133a in maintaining tissue homeostasis is becoming increasingly recognized
and these findings suggests that loss of miR133a-mediated translational control
of specific gene targets may contribute to pathological aortic remodeling.
However, the exact mechanism by which miR-133a may be reduced in thoracic
aortic tissue has yet to be defined.
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SPECIFIC AIMS
Therefore, the following studies tested the hypothesis that increased
thoracic aortic wall tension reduces miR-133a. Accordingly, a stepwise
approach will be utilized to test the following specific aims:

1) Demonstrate miR-133a is mechanosensitive. Utilizing murine aortic
rings in an ex vivo tissue myograph, and in vitro with isolated primary
aortic cells (fibroblasts and smooth muscle cells): demonstrate increased
tension alters the abundance of mature miR-133a.
2) Determine the mechanism of miR-133a reduction. In isolated aortic
fibroblasts: investigate the mechanism by which miR-133a is reduced
(transcriptional regulation, degradation, or regulated cellular export).
3) Demonstrate the effects of hypertension on miR-133a levels. Utilizing
two distinct in vivo murine models of hypertension (AngII induced
pretension and a spontaneously hypertensive mouse line), demonstrate
that hypertension is sufficient in alteration of miR-133a levels in thoracic
aortic tissue and plasma.
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CHAPTER 2: MicroRNA-133a is Mechanosensitive
INTRODUCTION
Mechanical factors play a significant role in the maintenance of vessel
homeostasis. Under normotensive conditions, a physiologically relevant level of
wall tension is essential for preserving normal vessel structure and function.(223)
However, conditions of increased vascular wall tension, for example,
hypertension, precipitates structural changes in the thoracic aorta (TA) as a
result of remodeling of the vessel wall leading to increased stiffness and often
dilation.(63, 232, 233) In this process, alterations in the expression and
abundance of multiple proteases involved in remodeling occurs, and this process
has been attributed to increased wall tension in the thoracic aorta.(234-236)
While alterations in microRNA levels have been associated with aortic
pathologies, the role of wall tension in this process remains unclear. The
microRNAs target short nucleotide sequences (seed regions) within the 3’
untranslated region (UTR) of specific messenger RNAs (mRNAs), and function to
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induce message degradation, destabilization, or more typically, translational
repression. Moreover, a single microRNA is capable of targeting multiple
mRNAs, and a single mRNA may contain multiple microRNA binding sites.(197,
237, 238). Therefore, alterations in microRNA levels may profoundly affect
cellular function.
A particular microRNA, miR-133a, has been demonstrated to regulate
adverse vascular remodeling in vivo (discussed in Chapter 1).(214) Previous
results from this laboratory determined in clinical specimens, miR-133a displays
an inverse linear correlation with aortic diameter, such that, as diameter
increased, the abundance of miR-133a was reduced.(212) Based on the
fundamentals of the Law of Laplace, we know that vessel wall tension is
dependent upon the relationship between pressure and diameter (wall tension =
pressure X diameter). Accordingly, during aneurysm formation wall tension
increases as the aorta dilates, and this may play a role in determining miR levels
in the thoracic aortic wall. Therefore, the objective of these studies was to
demonstrate mature miR-133a levels may be reduced with increased tension.

RESULTS
Increased mechanical tension reduces mature miR-133a in thoracic aortic
tissue.
To determine the effects of elevated applied tension on miR-133a levels,
intact murine TA segments (rings) harvested from wild-type, normotensive mice
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were hung on parallel wires in an ex vivo tissue myograph. Control thoracic
aortic segments were held at a previously determined level of tension (0.7 g) that
approximates in vivo normotension (mean arterial pressure (MAP), ~70 mmHg)
(234, 235) To simulate elevated wall tension (hypertension), an increased
amount of tension (1.5g, MAP ~150 mmHg) was applied directly to the aortic
segments for 3 hours. The abundance of mature miR-133a was reduced in
response to increased applied tension as compared to control segments
(0.31±0.08 vs 1.0±0.25 fold; p<0.05 vs control; n=7) (Figure 2.1).

Figure 2.1 Effects of applied ex vivo mechanical tension on miR-133a levels
in thoracic aortic rings. Descending aortae from wild-type C57BL/6 mice were
transversely cut into 3 mm rings and suspended in a tissue myograph on parallel
wires in oxygenated Krebs-Henseleit solution. Displayed is the fold change in
mature miR-133a abundance in aortic rings held at 0.7 g (Normotension, Control,
n=7) or with 1.5 g applied tension (Tension, n=7) for three hours. Data are
represented as mean ± SEM. Comparisons were made using a two-sample t-test
(unpaired, two-tailed). * p<0.05 vs. control.

57

Angiotensin II (AngII) is known to modulate adhesion molecules,
chemokines, cytokines, and growth factors that control cellular proliferation,
hypertrophy, fibrosis, and inflammation in the vessel wall.(85) Furthermore, it is
well described that AngII causes increased vascular resistance through
vasoconstriction which leads to elevated vascular wall tension.(84) Therefore,
we sought to determine the effects of developed tension in response to AngII on
the abundance of miR-133a.
Thoracic aortic rings from normotensive wild-type mice were hung on
parallel wires in an ex vivo tissue myograph and held at 0.7g tension, then were
exposed to 100nM AngII for three hours in an ex vivo tissue myograph.
Angiotensin II-dependent vessel contraction resulted in increased developed wall
tension compared to rings treated with vehicle (1.51±0.15 vs. 0.73±0.03g; p<0.05
vs control; n=8) (Figure 2.2 A). Following 3 hours of AngII-induced contraction,
miR-133a abundance was reduced compared to non-contracting rings treated with
vehicle (0.42±0.09 vs 1.0±0.22 fold; p<0.05 vs control; n=8) (Figure 2.2 B).
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Figure 2.2 Effects of generated ex vivo mechanical tension on miR-133a
levels in thoracic aortic rings. Descending aortae from wild-type C57BL/6 mice
were transversely cut into 3 mm rings and suspended in a tissue myograph on
parallel wires in oxygenated Krebs-Henseleit solution. (A) Peak generated tension
(grams) in aortic rings held at normotension (0.7 g) in the absence (Control, n=8)
or presence of 100nM AngII (AngII, n=8) for three hours. (B) Effect of generated
tension on miR-133a abundance in aortic rings held at normotension (0.7 g) in the
absence (Control, n=8) or presence of 100nM AngII (AngII, n=8). Data are
represented as mean ± SEM. Comparisons were made using a two-sample t-test
(unpaired, two-tailed). * p<0.05 vs. control.
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Increased mechanical tension results in reduced miR-133a abundance in
isolated thoracic aortic fibroblasts.
When isolated aortic fibroblasts and smooth muscle cells (SMCs) where
exposed to mechanical tension by biaxial cyclic stretch, mature miR-133a was
reduced in stretched fibroblasts as compared to static fibroblast controls
(0.21±0.02 vs 1.0±0.27 fold; p<0.05 vs control; n=8) (Figure 2.3). Interestingly, no
change in miR-133a abundance was observed in stretched SMCs (0.98±0.43 vs
1.0±0.12 fold; p=0.46 vs control; n=7) (Figure 2.4). These findings suggested
that the reduction in mature miR-133a observed in aortic tissue segments
exposed to elevated tension (Figure 2.1) may have been due to a corresponding
reduction of miR-133a in aortic fibroblasts.

Figure 2.3 Effects of mechanical tension on miR-133a levels in isolated
thoracic aortic fibroblasts. Aortic fibroblasts were isolated from the descending
aortae from C57BL/6 mice. Displayed is the fold change in mature miR-133a
abundance measured in aortic fibroblast lines following exposure to 3 hours of 12%
biaxial cyclic stretch (Tension, n=8) or held static (Control, n=8). Data are
represented as mean ± SEM. Comparisons were made using a two-sample t-test
(unpaired, two-tailed). * p<0.05 vs. control.
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Figure 2.4 Effects of mechanical tension on miR-133a levels in isolated
thoracic aortic smooth muscle cells. Aortic smooth muscle cells were isolated
from the descending aortae from C57BL/6 mice. Displayed is the fold change in
mature miR-133a abundance measured in aortic SMC lines following exposure to
3 hours of 12% biaxial cyclic stretch (Tension, n=7) or held static (Control, n=7).
Data are represented as mean ± SEM. Comparisons were made using a twosample t-test (unpaired, two-tailed). No significant differences were observed vs.
control.

To determine whether AngII receptor signaling was contributing to the loss
of mature miR-133a, isolated primary aortic fibroblasts and SMCs were exposed
to 100 nM AngII for 3 hours. No change in miR-133a was observed in fibroblasts
(1.20±0.52 vs 1.0±0.27 fold; p=0.62 vs control, n=8) (Figure 2.5 A) or SMCs
(1.14±0.26 vs 1.0±0.11 fold; p=0.69 vs control; n=7) (Figure 2.5 B). These
findings suggested the alterations in miR-133a observed in the aortic ring
segments was likely due to the direct effects of mechanical tension on the
fibroblasts within the aortic wall, with no contribution of AngII-mediated receptor
signaling.
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Figure 2.5 Effects of angiotensin-II on miR-133a levels in isolated thoracic
aortic fibroblasts and smooth muscle cells. Aortic fibroblasts and smooth
muscle cells were isolated from the descending aortae from C57BL/6 mice. (A)
MiR-133a abundance was measured in aortic fibroblasts lines treated without
(Control, n=8) or with 100nM AngII (AngII, n=8) for three hours. (B) MiR-133a
abundance was measured in aortic SMC lines treated without (Control, n=7) or
with 100nM AngII (AngII, n=7) for three hours. Data are represented as mean ±
SEM. Comparisons were made using a two-sample t-test (unpaired, two-tailed).
No significant differences were observed vs. control.
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SUMMARY
These results demonstrate elevated tension applied to the murine thoracic
aorta ex vivo reduced miR-133a and biaxial cyclic stretch reduced miR-133a in
murine thoracic aortic fibroblasts, while no change was observed in smooth
muscle cells. Furthermore, AngII induced aortic contraction and reduced aortic
tissue miR-133a abundance; however, this effect was likely a result of the
mechanical tension, as AngII had no effect on miR-133a levels in isolated
thoracic aortic fibroblasts or SMCs.
The unique findings of this investigation were two-fold. First, it was
determined that ex vivo tension applied to intact thoracic aortic rings resulted in
an acute reduction in tissue miR-133a abundance. Second, mechanical tension
in the form of biaxial cyclic stretch applied to isolated primary aortic cells
(fibroblasts and smooth muscle cells) revealed that fibroblasts preferentially
responded to mechanical tension, resulting in the acute reduction of miR-133a.

DISCUSSION
MicroRNAs constitute a novel class of 20-25 nucleotide small non-coding
RNA molecules that target short sequences within the 3’-untranslated region of
specific messenger RNAs, and function to fine-tune protein abundance by
inducing message destabilization, degradation, or more commonly, translational
repression.(237) To date, nearly 2000 unique high confidence miRNAs have
been identified in the human genome (mirbase.org). Importantly, it has been well
described that a single miR can target multiple mRNAs, and that a single mRNA
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can contain multiple miR binding sites.(197, 198) This suggests that miRs, alone
or in combination, may be able to regulate a coordinated cassette of genes that
together can influence specific cellular functions. Previous work from this
laboratory demonstrated that the abundance of miR-133a was decreased in
aortic tissue from patients with TAA, and was inversely proportional to aortic
diameter.(212) We hypothesized, based on the Law of Laplace, that the
elevated wall tension, as experienced with increased aortic diameter, may play a
role in regulating miR-133a cellular abundance.

It is well described that mechanical tension applied to a tissue is
transmitted through constituents of the extracellular matrix (ECM) to the resident
cells, and that this is a mechanism by which cellular and tissue homeostasis may
be regulated.(239) This process, known as mechanotransduction, affords cells
the ability to convert mechanical cues from the physical environment into
biochemical or transcriptional changes at the cellular level.(240, 241) The
association between increased wall tension and vascular remodeling, as
observed in intimal hyperplasia,(242) or aortic aneurysm disease,(63) is well
described. In previous results from this laboratory, mechanical tension applied to
intact murine thoracic aortic rings was sufficient to alter the gene expression of
several key matrix metalloproteinases (MMPs) active in ECM remodeling, such
as, MMP-2 and the membrane type-1 MMP (MT1-MMP).(234, 235) Combined
with previous findings demonstrating that miR-133a has the capacity to regulate
the abundance MT1-MMP,(222, 243) these prior studies provided foundational
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evidence that justified investigation into the effects of mechanical tension on the
levels of miR-133a. In the present report, a similar approach was taken by
directly applying tension to intact aortic rings ex vivo in order to identify the
effects of acute elevated tension on the tissue levels of mature miR-133a. The
results demonstrated that, in as little as 3 hours of applied tension (roughly
equivalent to a MAP of ~150 mmHg), tissue levels were reduced by
approximately 70%. This is in agreement with a recent study by Mohamed and
colleagues whom performed a genome wide analysis on the dysregulation of miR
abundance in the diaphragm of mice following ex vivo application of transverse
mechanical tension.(244) In this study using microRNA microarray analysis, the
authors demonstrated that multiple miRs were affected by the application of
mechanical tension relative to control; applied tension increased the abundance
of some microRNAs and also decreased the abundance of others, including miR133a.(244) The present study added to these findings by confirming miR-133a is
a mechanically sensitive miR and levels are subject to an acute reduction
through the application of tension.
While the use of ex vivo mechanical tension has allowed for the ability to
isolate the effects of wall tension alone on miR-133a levels, multiple factors
influence wall tension in vivo. It is well known that Angiotensin-II (AngII) causes
increased peripheral vascular resistance through vasoconstriction which leads to
elevated vascular wall tension,(84) and it has long since been recognized that
circulating levels of AngII are elevated in patients with essential
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hypertension.(245, 246) Furthermore, AngII is known to modulate adhesion
molecules, chemokines, cytokines, and growth factors that control cellular
proliferation, hypertrophy, fibrosis, and inflammation in the vessel wall.(85)
Therefore, with the use of AngII, we sought to determine the effects of a
physiologically relevant form of developed tension on the abundance of miR133a. Interestingly, this developed tension had a similar effect to the direct
application of tension, acutely reducing the abundance of miR-133a, highlighting
the physiological relevance of this observation in conditions of elevated wall
tension, such as with hypertension.
Further exploration into the effects of tension on miR-133a abundance in
two major cell types of the aorta identified that biaxial cyclic stretch also led to the
acute reduction of miR-133a in fibroblasts while SMCs were not responsive. This
finding identified an unexpected differential response in these two aortic cell
types. Previous studies have suggested that fibroblasts are sensitive to changes
in mechanical tension and can respond by altering their phenotypic
characteristics, taking on a more “synthetic” or mobile role when exposed to
increased tension.(239, 247) In pathological vascular remodeling, these
synthetic fibroblasts become activated in the adventitia, and migrate inward
remodeling the extracellular matrix and enhance vessel stiffness.(167) Previous
results from this laboratory have defined changes in the cellular makeup within
the aortic wall during TAA formation, revealing that aortic dilation occurs
simultaneously with vessel wall remodeling and the emergence of a population of
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active fibroblasts.(94) When combined with previous studies demonstrating that
aortic dilation is accompanied by the apoptotic loss of SMCs,(248) it is believed
that the fibroblasts may be the key cellular mediator of aortic remodeling in
aneurysm development.(195) As a single microRNA may regulate translation of
multiple targets, the present results, identifying an acute reduction of miR-133a in
aortic fibroblasts as a result of increased mechanical tension, may provide insight
in the phenotypic alterations observed in these activated fibroblasts and are
studies warranting future investigation. Interestingly, when the isolated
fibroblasts and SMCs were exposed to AngII, no change in miR-133a levels were
observed. This finding suggests the alterations in miR-133a earlier observed in
the aortic ring segments were not a direct result of AngII-mediated receptor
signaling in the aortic fibroblasts or SMCs, but were likely due to the direct effects
of mechanical tension on the fibroblasts within the aortic wall.

LIMITATIONS
The present study is not without limitations. First, the use of ex vivo aortic
tissue segments raised the concern of tissue viability throughout the duration of
the three-hour study. To address this, parallel studies have been performed in
which aortic rings were hung for three hours on the tissue myograph, then
stimulated to contract with potassium chloride (KCl). The ability of the tissue to
mount a contractile response suggests preservation of tissue viability.(234)
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CONCLUTIONS
Regulation of genes by mechanical force is a well describe
occurrence.(234, 235) More recently, focus has shifted toward tension induced
alterations in microRNA levels due to the profound effect on translation. The
focus on miR-133a is of particular importance due to the strong association
between reduced levels and cardiovascular disease.
Importantly, fibroblasts have been identified as a cell type that is sensitive
to mechanical tension and subject to undergo changes, taking on “synthetic” or
mobile characteristics. In pathological vascular remodeling, these synthetic
fibroblasts become activated in the adventitia, and migrate inward disrupting the
extracellular matrix and increase vessel stiffness.(167)
Combined with previous studies which have demonstrated aortic dilation is
accompanied by the apoptotic loss of SMCs,(248) it is believed that the
fibroblasts may be the key cellular mediator of aortic remodeling.(195) These
changes in functional and structural behavior of the fibroblasts exposed to
tension may be, in part, due to the early and rapid reduction of miR-133a.
Therefore, identification of the mechanisms involved in the reduction of miR-133a
may have potential therapeutic application.
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CHAPTER 3: A mechanism for tension induced
reduction of miR-133a
INTRODUCTION
The vast role microRNAs play in the regulation of translation suggests that
microRNAs must themselves be regulated. There are three basic cellular
functions that can contribute to the regulation of miR-133a cellular abundance:
transcriptional regulation, microRNA degradation, and regulated cellular export.
Currently, the majority of literature on microRNA regulation suggests that
expression is largely controlled on the transcriptional level. Like all messenger
RNAs (mRNAs), microRNAs are transcribed from DNA by an RNA polymeraseII-dependent process.(149) However, microRNA genes are often embedded in
introns or exons (on the reverse DNA strand) of other genes. MicroRNA-133a
and miR-1 are included in the same bicistronic unit and are encoded in two
locations within the genome; miR-133a-1/miR-1-2 (embedded in an intron of the
Mib-1 gene, located on chr18 in mice and humans) and miR-133a-2/miR-1
(located on chr20 in humans and chr2 in mice).(249) The transcriptional
regulatory elements of microRNAs, such as DNA binding factors, promoter
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structure and histone modifications, largely overlap with that of mRNAs.(201,
202) MiR-133a, has been demonstrated to be regulated by transcription factors,
such as, MyoD, Mef2, and SRF.(218, 250) Furthermore, an association of
histone deacetylate 1 and 2 has been identified with the miR-133a enhancer
region, suggesting the possibility for epigenetic regulation.(218) Independent of
the specific mechanism, altered microRNA transcription affects the cellular level
of primary microRNA (pri-microRNA), and ultimately the abundance of the
mature form.(218)
Mature microRNA abundance may be regulated post-transcriptionally via
regulated degradation.(251) MicroRNAs have been demonstrated to be highly
stable in circulating plasma (252) and in cells, having a prolonged half-life
roughly 2- to 20 times longer than that of typical mRNAs.(253, 254) Recent
studies have shown that individual microRNAs may be subject to accelerated
decay under certain conditions,(255) and this has been attributed to active
degradation by microRNA specific exoribonucleases.(256-258) Three microRNA
specific exoribonucleases have been identified in mammalian cells (XRN-1,
XRN-2, and ExoSC4), and knockdown of these exoribonucleases have resulted
in the accumulation of multiple mature microRNAs.(255-258) Chatterjee et. al
demonstrated in C. elegans, that siRNA mediated knockdown of XRN-1 led to
the accumulation of let-7 microRNA, while levels of primary and precursor let-7
microRNA remained unchanged;(258) however, in another study, siRNA against
XRN-2 led to a greater than 2 fold increase in only 7 of the twelve microRNAs
tested.(257) Interestingly, another study examining the effects of
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exoribonuclease degradation on miR-382 levels, demonstrated that knockdown
of ExoSC4 by shRNA affected miR-382 abundance, while knockdown of XRN-2
had no measurable differences.(256) These interesting and differing effects lead
one to conclude that different microRNAs are likely targeted by distinct nucleases
for decay.
Mature microRNA abundance may also be reduced at the posttranscriptional level by regulated cellular export.(259, 260) Exosomes are small
lipid vesicles, with bilayer membranes, that encapsulate many different RNAs,
proteins, lipids, and microRNAs. Exosomes are derived from the endo-lysosomal
pathway, and are actively secreted from a wide variety of cell types. Formation of
exosomes begins with the incorporation of endosomes into multivesicular bodies
and this process is dependent on the activity of neutral sphingomyelinase 2
(nSMase2).(261, 262) Cellular secretion of exosomes occurs following fusion of
the multivesicular body with the plasma membrane.(263)
Accordingly, this set of investigations will seek to determine a mechanism
responsible for the tension induced reduction of miR-133a in aortic fibroblasts by
focusing on three major pathways of microRNA regulation, transcriptional
regulation, degradation, or regulated cellular export.
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RESULTS
Mechanical tension does not reduce transcription of miR-133a in thoracic
aortic fibroblasts.
To determine the mechanism of tension-induced loss of mature miR-133a,
primary (pri-) miR-133a transcript levels (pri-miR-133a-1 and pri-miR-133a-2)
were measured in isolated aortic fibroblasts following biaxial cyclic stretch. The
expression of pri-miR-133a-1 did not change in response to mechanical stretch
(1.14±0.33 vs 1.0±0.26 fold; p=0.62 vs control; n=8) (Figure 3.1 A), while the
expression of pri-miR-133a-2 increased in response to stretch (2.0±0.44 vs
1.0±0.21 fold; p<0.05 vs control; n=8) (Figure 3.1 B). The results suggested that
the tension-induced loss of mature miR-133a occurred post-transcriptionally.
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A

B

Figure 3.1. Mechanical tension and transcription of pri-miR-133a-1 and primiR-133a-2. Total RNA was isolated from each individual cell line, and primarymiR-133a levels were determined by real-time PCR. (A) Pri-miR-133a-1
expression levels in aortic fibroblasts exposed to 12% biaxial cyclic stretch
(Tension, n=8) or held static (Control, n=8) for three hours. (B) Pri-miR-133a-2
expression levels in aortic fibroblasts exposed to 12% biaxial cyclic stretch
(Tension, n=8) or held static (Control, n=8) for three hours. Data are represented
as mean ± SEM. Comparisons were made using a two-sample t-test (unpaired,
two-tailed). * p<0.05 vs. control.
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Increased mechanical tension does not alter the expression or abundance
of microRNA specific exoribonucleases in thoracic aortic fibroblasts.
While mature microRNAs are not likely substrates for most
endoribonucleases, (255, 264) they do possess unprotected 5' and 3' ends
making them susceptible to degradation by specific exoribonucleases.(253, 256)
Three exoribonucleases that are capable of degrading microRNAs have been
identified, XRN-1(258), XRN-2 (257, 258), and ExoSC4 (256). To examine
whether mechanical tension induced these exoribonucleases, the mRNA
expression and protein levels of XRN-1, XRN-2, and ExoSC4 were measured in
isolated aortic fibroblasts following biaxial cyclic stretch. Neither the mRNA
expression nor protein abundance of these exoribonucleases were changed
compared to static fibroblasts; XRN-1 mRNA: 1.44±0.29 vs 1.0±0.47 fold, n=9,
p=0.197 (Figure 3.2 A); XRN-1 protein: 0.86±0.14 vs 1.0±0.17 fold, n=9, p=0.555
(Figure 3.2 B); XRN-2 mRNA: 0.82±0.08 vs 1.0±0.42 fold, n=9, p=0.286 (Figure
3.3 A); XRN-2 protein: 0.93±0.29 vs 1.0±0.18 fold, n=5, p=0.851 (Figure 3.3 B);
ExoSC4 mRNA: 0.70±0.07 vs 1.0±0.20 fold, n=9, p=0.166 (Figure 3.4 A);
ExoSC4 protein: 1.0±0.09 vs 1.0±0.10 fold, n=5, p=0.992 (Figure 3.4 B). These
findings suggest that the tension-induced loss of miR-133a in fibroblasts was not
mediated by the rapid degradation of mature miR-133a.
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Figure 3.2. Mechanical tension and XRN1 mRNA expression and protein
abundance. Total RNA or protein was isolated from each independent cell line
and examined by real-time PCR or Western blotting, respectively. (A) XRN1 mRNA
expression levels in aortic fibroblasts exposed to 12% biaxial cyclic stretch
(Tension, n=9) or held static (Control, n=9) for three hours. (B) XRN1 protein
abundance and representative immunoblot in aortic fibroblasts exposed to 12%
biaxial cyclic stretch (Tension, n=5) or held static (Control, n=5) for three hours.
Data are represented as mean ± SEM. Comparisons were made using a twosample t-test (unpaired, two-tailed). No significant differences were observed vs.
control.
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Figure 3.3. Mechanical tension and XRN2 mRNA expression and protein
abundance. Total RNA or protein was isolated from each independent cell line
and examined by real-time PCR or Western blotting, respectively. (A) XRN2 mRNA
expression levels in aortic fibroblasts exposed to 12% biaxial cyclic stretch
(Tension, n=9) or held static (Control, n=9) for three hours. (B) XRN2 protein
abundance and representative immunoblot in aortic fibroblasts exposed to 12%
biaxial cyclic stretch (Tension, n=5) or held static (Control, n=5) for three hours.
Data are represented as mean ± SEM. Comparisons were made using a twosample t-test (unpaired, two-tailed). No significant differences were observed vs.
control.
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Figure 3.4. Mechanical tension and ExoSC4 mRNA expression and protein
abundance. Total RNA or protein was isolated from each independent cell line
and examined by real-time PCR or Western blotting, respectively. (A) ExoSC4
mRNA expression levels in aortic fibroblasts exposed to 12% biaxial cyclic stretch
(Tension, n=9) or held static (Control, n=9) for three hours. (B) ExoSC4 protein
abundance and representative immunoblot in aortic fibroblasts exposed to 12%
biaxial cyclic stretch (Tension, n=5) or held static (Control, n=5) for three hours.
Data are represented as mean ± SEM. Comparisons were made using a twosample t-test (unpaired, two-tailed). No significant differences were observed vs.
control.
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A Prologue to Extracellular Vesicles
First described in 1985, extracellular vesicles have since become a topic
of growing interest. Initially studied in blood cells, it was known that reticulocyte
maturation into mature erythrocytes required the rapid loss (<24 hours) of the
transferrin receptor; however, this receptor was not reduced by degradation, as
the full, un-cleaved receptor was able to be recovered from culture media.(265267) Pan et al. demonstrated that reticulocyte maturation required the shedding
of the cellular component, transferrin, via vesicle secretion in order to
differentiate into a mature erythrocyte.(268, 269) Since this observation, a wide
variety of cellular components were discovered to be encapsulated within these
vesicles and secreted from many different cell types in normal and pathological
conditions. Importantly, in 2008, it was discovered extracellular vesicles contain
microRNAs.(260) While the destiny of extracellular vesicles is currently under
debate, it has long since been recognized that a function of vesicle secretion is to
export cellular components allowing for elimination. This is an especially
important mechanism during cellular transformation when relatively stable
molecules must be removed to optimize new function.(270)
Two classes of extracellular vesicles have been described; microvesicles
and exosomes, and each have distinct biogenesis pathways. (Figure 3.5)
Microvesicles are lipid bilayer vesicles, approximately 100-1000nm in diameter
and form by outward budding of the plasma membrane and subsequent fission
resulting in release. During abscission, the molecule ARF6 facilitates the
trafficking of lipid rafts in the plasma membrane, regulating contractile machinery
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Figure 3.5. Classes of extracellular vesicles. A summary of extracellular
vesicle biogenesis. While microRNAs are incorporated in both microvesicles and
exosomes, production of each vesicle type by cells is distinct. Microvesicles are
generated on the cell surface and are formed through the outward budding of the
plasma membrane. Exosomes are formed via a regulated and ceramide
dependent mechanism by incorporation of endosomes into a mutivecicular body
then shuttling to the cell surface and subsequent release. A-E are the different
forms in which microRNAs may be found within extracellular vesicles. Reproduced
with permission from Springer. License ID: 4127100107596.

within the cleavage furrow, drawing the opposing membrane together before
pinching off and shedding into the extracellular space.(271, 272) Exosomes are
lipid bilayer vesicles approximately 30-100nm in diameter and originate from the
endo-lysosomal pathway when multivesicular bodies fuse with the plasma
membrane. Exosomes are released from cells through a ceramide-dependent
secretory pathway.(273) The release of Ceramide from sphingomylinin is
regulated by neutral sphingomylenase 2 (nSMase2), which regulates the
formation and packaging of exosomes within the multivesicular body.(261)
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Exosomes are released into the extracellular space upon fusion with the plasma
membrane, which is mediated by GTPases, such as RAB27a.(274)
The ceramide dependent microRNA cargo sorting mechanism of
exosomes is far better understood than that of microvesicles. Kosaka et al.
found that overexpression of nSMase2 increased ceramide and the amount of
exosomal microRNAs, while knockdown of nSMase2 by siRNA reduced
exosomal microRNAs.(262) Furthermore, it is believed that exosome packaging
and sorting is far more specific than that of microvesicles, which is a process that
is not fully understood.(263) Therefore, this set of investigations will focus
specifically on the exosome pathway as a possible mechanism for the reduction
of cellular miR-133a.

Mechanical tension induces exosome secretion of miR-133a.
To determine the effects of stretch on exosome secretion, fibroblasts were
exposed to biaxial cyclic stretch for 18 hours in media containing exosome
depleted fetal bovine serum. Following stretch, the media was collected and the
newly secreted exosomes were precipitated. Acetylcholinesterase (AChE) is
enriched in the lipid bilayer membrane of exosomes,(269, 275, 276) allowing the
measurement of AChE activity to be used as a surrogate for the number of
exosomes present (275, 277). Acetylcholinesterase activity was higher in
exosomes precipitated from the media of fibroblasts exposed to stretch as
compared to static control fibroblasts (1.27±0.04 vs 1.0±0.08 fold; p<0.05; n=8)
80

(Figure 3.6 A). Furthermore, the abundance of miR-133a was increased in the
exosomes collected from the fibroblasts exposed to stretch when compared to
static control (1.65±0.28 vs 1.0±0.12 fold; p<0.05; n=7) (Figure 3.6 B). These
results demonstrated that stretch induces exosome secretion of miR-133a in TA
fibroblasts.
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Figure 3.6 Mechanical tension and exosome secretion. Exosomes were
precipitated from conditioned culture media from each fibroblast line. (A)
Acetylcholinesterase (AChE) activity was quantitated as a measure of exosome
number from each fibroblast line exposed to 12% biaxial cyclic stretch (Tension,
n=8) or held static (Control, n=8) for 18 hours. (B) MiR-133a abundance in
exosomes precipitated from the conditioned media of each fibroblast cell line
exposed to 12% biaxial cyclic stretch (Tension, n=7) or held static (Control, n=7)
for 18 hours. Data are represented as mean ± SEM. Comparisons were made
using a two-sample t-test (unpaired, two-tailed). * p<0.05 vs. control.
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The secretion of exosomes is dependent upon the formation of the
sphingolipid ceramide.(261) Neutral sphingomyelinase 2 (nSMase2), regulates
the abundance of ceramide by mediating its release from sphingomyelin.(278,
279) Inhibition of nSMase2 with the use of a well-describe non-competitive
inhibitor (GW4869) has been demonstrated to prevent the secretion of
exosomes.(261, 280-282) Accordingly, to demonstrate that stretch-induced
secretion of miR-133a was mediated by exosome secretion, fibroblasts were
exposed to stretch in the presence of GW4869. Inhibition of exosome formation
prevented the stretch-induced secretion of miR-133a; no change in cellular miR133a levels were observed with GW4869 as compared to static control
(1.02±0.35 vs 1.0±0.29 fold; p=0.52, n=8) (Figure 3.7). Taken together, these
studies suggest that one mechanism by which miR-133a is lost in response to
elevated mechanical tension is through increased packaging and release of miR133a in exosomes.
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Figure 3.7 Mechanical tension and exosome secretion of miR-133a. Aortic
fibroblasts were isolated from the descending aortae from C57BL/6 mice and
exosome secretion was inhibited with GW4869. miR-133a abundance was
quantitated in each aortic fibroblast line following exposure to 3 hours of 12%
biaxial cyclic stretch in the presence of 20uM GW4869 (Tension+GW4869, n=8)
or held static (control, n=8). Data are represented as mean ± SEM. Comparisons
were made using a two-sample t-test (unpaired, two-tailed). No significant
differences were observed vs. control.

SUMMARY
There is growing evidence focusing on the significance of microRNA
export via exosomes.(283) Therefore, the effect of mechanical tension on
exosome secretion of miR-133a was examined in isolated aortic fibroblasts.
Acetylcholinesterase activity was demonstrated to be increased in the
precipitated extracellular vesicles from the media of fibroblasts exposed to cyclic
stretch. This finding may suggest either an increase in extracellular vesicle
number or size. Nevertheless, more miR-133a was detected in the extracellular
vesicles collected from the media of fibroblasts exposed to stretch. Increasing
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evidence suggests microRNAs are not randomly incorporated into extracellular
vesicles,(284-286) and several reports have indicated that microRNA abundance
within extracellular vesicles is altered in pathology.(287) In agreement with these
previous studies, the present results suggest miR-133a may be preferentially
incorporated into these vesicles and secreted from fibroblasts exposed to stretch.
Cargo sorting mechanisms to exosomes are far better understood than
that of microvesicles, and one mechanism regulating the secretion of exosomes
is a nSMase2-dependent pathway.(262) The effect of inhibiting nSMAse2 with
the use of GW4869 (hydrochloride hydrate) prevented stretch-induced reduction
of miR-133a from fibroblasts, confirming that exosomes are responsible for
mediating secretion of miR-133a.

DISCUSSION
In the present study, we examined mechanisms capable of regulating miR
abundance under conditions of elevated wall tension. Accordingly, three
potential mechanisms capable of regulating the cellular abundance of miRs were
examined. The unique findings of this set of investigations demonstrated that
tension-dependent loss of miR-133a was primarily mediated through exosome
formation and release. These results identified a specific tension-sensitive
mechanism by which miR-133a was reduced in a specific aortic cell-type
(fibroblasts) that plays a key role in adverse vascular remodeling.
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We and others have demonstrated that mechanical tension is sufficient in
altering transcription.(234, 235, 288) To determine if the reduction of miR-133a
in aortic fibroblasts was due to reduced transcription, primary (pri-) microRNA133a transcript levels were quantitated following the application of mechanical
tension. Production of mature microRNAs begins with the synthesis of primicroRNAs.(203) While multiple factors regulate transcription (e.g. transcription
factors, binding of RNA polymerase II to the DNA, histone methylation), a
reduction in mature microRNA abundance resulting from a decrease in
transcription would be observed by the detection of reduced primary microRNA
transcript levels. As miR-133a is transcribed from two separate locations within
the genome, both pri-miR-133a-1 and pri-miR-133a-2 were examined. Although
mechanical tension had no effect on pri-miR-133a-1 levels, it did induce an
increase in pri-miR-133a-2 levels. This, however, was not sufficient to overcome
the loss of total mature miR-133a observed. Therefore, it was concluded, that the
tension induced reduction of mature miR-133a in fibroblasts was not a result of
changes in transcription, suggesting that the reduction likely occurred posttranscriptionally.
One post-transcriptional mechanism responsible for decreasing mature
miR levels includes degradation by ribonucleases. Mature microRNAs have 5’
and 3’ unprotected ends that render them accessible to specific
exoribonucleases. Three known exoribonucleases capable of degrading miRs
have been identified (XRN-1, XRN-2, and ExoSC4).(253, 256) While the exact
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mechanisms involved in microRNA degradation are largely unknown, it has been
demonstrated that the exoribonucleases facilitate the release of microRNAs from
the RISC, followed by subsequent degradation.(253, 257) Interestingly, in these
previous reports it was also demonstrated that degradation of the microRNAs by
exoribonuclease activity did not appear to depend on sequence context.
Nevertheless, rapid decay of microRNAs is a highly efficient mechanism in
regulating cellular abundance.
Therefore, the effects of mechanical tension on these 3 exoribonucleases
were examined. Results demonstrated that their mRNA expression and protein
abundance remained unchanged in the presence of elevated mechanical
tension. It remains unclear whether other mechanisms, such as regulated
activation of XRN1, XRN2 or ExoSC4, may show mechanosensitivity, however
additional studies would be warranted to examine that hypothesis. Nevertheless,
these results suggested that rapid degradation of miR-133a was not likely
mediated by a degradation pathway in response to elevated tension.
There is growing evidence focusing on the significance of microRNA
export via exosome secretion.(283) The majority of recent literature surrounding
exosome secretion focuses on the trafficking of exosomes and regulation of
recipient cell activity through the transport of lipids, proteins, and nucleic acids;
however, exosome secretion has also been identified as an efficient mechanism
for the rapid reduction of cytoplasmic nucleic acids.(11) Therefore, the effect of
mechanical tension on exosome secretion of miR-133a was examined in isolated
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aortic fibroblasts. Acetylcholinesterase (AChE), which is widely produced outside
of the nervous system by a variety of cell types, including fibroblasts (289), is
enriched in the lipid bilayer membrane of exosomes,(269, 275, 276) therefore
allowing for an estimation in the relative amount of exosomes by quantitation of
AChE activity (275, 277). Following application of tension, AChE activity was
increased in the precipitated exosomes isolated from the media of fibroblasts
exposed to cyclic stretch, suggesting either an increase in exosome size or
number. Nevertheless, when normalizing for the amount of AChE activity, more
miR-133a was detected in the exosomes collected from the media of fibroblasts
exposed to stretch, suggesting increased packaging as well as increased export.
Evidence exists suggesting that microRNAs are not just randomly incorporated
into exosomes,(284-286) and reports have indicated that microRNA content
within exosomes is altered in pathologic conditions, such as cancer (287) and
cardiovascular disease (290). In agreement with these previous studies, the
present results suggest miR-133a may be preferentially incorporated into
exosomes and secreted from fibroblasts exposed to elevated tension. One
mechanism regulating the secretion of exosomes is a neutral sphingomyelinase2 (nSMase2) dependent pathway.(262) The effect of inhibiting nSMAse2 with
the use of GW4869 prevented the tension-induced reduction of miR-133a in
fibroblasts, suggesting that secretion of exosomes containing miR-133a is a
mechanism responsible for the rapid loss of miR-133a from aortic fibroblasts in
the presence of elevated mechanical tension.
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A wide variety of molecules are contained in exosomes, including proteins,
lipids, nucleic acids, and microRNAs.(291) Current evidence supports the notion
that microRNAs are actively sorted into exosomes; however, the regulating
mechanisms responsible for selective incorporation are largely unknown. Goldie
and colleagues performed a total RNA analysis on exosomal RNA content
released from neuroblastoma cells and determined that the microRNAs comprise
the largest proportion of small RNAs.(292) Furthermore, this study determined
that the percentage of microRNAs in the total small RNA pool was higher in
exosomes than in the parent cells, suggesting that microRNAs may be
preferentially incorporated in exosomes. In support of this finding, GuduricFuchs et al. analyzed microRNA expression in a variety of cell lines and their
respective derived exosomes and found a subset of microRNAs that were
enriched in exosomes.(286) Specifically, it was determined that miRs -451, -150,
-146a, -320c, -143, -720, -125a, -486, -149, and -2110 are preferentially
incorporated in exosomes, while miRs -218, -15a, -140, -148b, -378, -16, -20a, 424, -18a, and let-7f are preferentially retained within the cell. Combined, these
studies demonstrate that certain microRNAs are preferentially sorted to
exosomes.
More recently, it has been identified that the abundance/profile of
microRNAs within exosomes is altered in several pathologies. For example,
Skog and colleagues identified increased miR-21 abundance in exosomes
isolated from the plasma of patients with glioblastoma.(287) However, the
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mechanisms mediating this preferential incorporation as well as the functional
role this characteristic plays in pathology are largely unknown.
Several recent studies have begun to unravel the complex mechanisms
involved in the selective shuttling of microRNAs into exosomes(293-296).
Although the underlying mechanisms remain largely unknown, two different
sorting pathways have been identified thus far. These pathways include a
sequence dependent mechanism, requiring the presence of a sequence motif
located in the 3’ end of the microRNA itself, and the second pathway is
dependent on interaction with certain proteins. (296-299)
Villarroya-Beltri and colleagues determined that when the heterogenous
nuclear ribonucleoproteins (hnRNP) becomes sumoylated, it binds to a GGAG
motif in the 3’ portion of a microRNA sequence, initiating incorporation of
microRNAs containing that specific sequence into exosomes.(293) This study
further identified that two other hnRNP proteins, hnRNPA1 and hnRNPC, bind to
microRNAs; however, the study was unable to determine any common binding
motifs among the 3’ sequences of the associated microRNAs confounding the
specific targeting mechanisms involved. Alternatively, Kopper-Lalic and
colleagues demonstrated that microRNAs possessing a 3’ uridylated tail were
preferentially incorporated in exosomes derived from B cells, while microRNAs
with an adenylated 3’ end were mainly present within the B cells.(294) While this
study identified that 3’ uridylation of microRNAs results in preferential
incorporation in exosomes, a mechanism mediating the actual shuttling into the
90

exosome was not determined. Both the hnRNP dependent sorting mechanism,
and the notion that microRNAs with a 3’ uridylated end are preferentially
incorporated in exosomes, implicates the 3’ portion of the microRNA sequence
as a possible sorting signal.
Several more recent studies have identified a possible correlation between
specific proteins and exosomal incorporation of microRNAs. It is known that
multivesicular bodies associate with components of microRNA effector
complexes and this may be key in shuttling of microRNAs to exosomes.(295)
First, an RNA binding protein, the Y-box Protein 1 (YBX1) has been identified to
have the ability to regulate the incorporation of miR-223 into exosomes.(296)
While these studies demonstrate the function of this interaction, all experiments
were performed in a cell-free biochemical assay. Whether and to what degree
this interaction occurs in vivo, and also if it occurs with other microRNAs, remains
to be determined. Second, the Argonaute 2 (Ago2) protein, which is required for
microRNA-mediated repression of translation by the RNA-induced silencing
complex (RISC),(297) has been demonstrated to be associated with microRNAs
in exosomes.(300, 301) Activation of the KRAS oncogene, which is largely
involved in the regulation of cell division,(298) was demonstrated to activate the
mitogen-activated protein kinase kinase/extracellular-signal-regulated kinase
(MEK-ERK) pathway, inhibiting the sorting of Ago-2 associated microRNAs -100,
-320a, and Let-7a into exosomes.(299) Thus, McKenzie and colleagues
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established a molecular mechanism responsible for regulating the sorting of
microRNA from the cytosol into exosomes.
In summary, specific sequences present in certain microRNAs may act in
the incorporation of exosomes, while a possible sequence independent
mechanism involving Ago2 may control sorting into exosomes. While the present
work identified that miR-133a is reduced in thoracic aortic fibroblasts via
exosome secretion, it remains to be determined if miR-133a is preferentially
incorporated in exosomes by a tension sensitive mechanism involving any of the
above mechanisms, and studies aimed at determining underlying mechanism
responsible warrant future investigation.

LIMITATIONS
The present study is not without limitations. This study was limited to the
investigation of the effects of tension on miR-133a only. While increasing
evidence highlights the role miR-133a plays in maintaining tissue homeostasis, it
is anticipated that the abundance of other microRNAs may also be altered with
elevated tension, and therefore may have an overall effect on the phenotypic
characteristics of resident cells or the development of pathology. Accordingly, we
are unable to conclude whether tension-induced secretion of miR-133a in
exosomes is limited to miR-133a, or is a characteristic of a specific group of
miRs. Studies focused on the identification of tension-sensitive miRs may reveal
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further insight as to overall effects of elevated tension. Furthermore, whether
and to what degree the observed reduction in mature miR-133a has on the
abundance of specific gene targets, as well as, the overall effect of miR-133a
reduction on cellular phenotype are studies that warrant future investigation.
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CONCLUSIONS
Alterations in microRNA (miR) abundance have been associated with
multiple cardiovascular diseases, and while much effort has been directed toward
understanding their role in modulating key cellular targets, less is known about
how miR abundance is regulated within the cell.(212-218) Previously, it was
identified that elevated tension results in the acute reduction of miR-133a in
thoracic aortic fibroblasts (discussed in Chapter 2). Accordingly, three potential
mechanisms capable of regulating the cellular abundance of miRs were
examined. The unique results of this set of investigations have identified a
specific tension-sensitive mechanism by which miR-133a was reduced in aortic
fibroblasts through the packaging and secretion of exosomes. While the direct
effects of in vivo wall tension on miR-133a abundance remains to be defined,
these current findings may lead to the development of novel pharmacotherapies
directed at inhibiting the secretion of miR-133a from aortic fibroblasts.
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CHAPTER 4: Effects of hypertension on miR-133a
levels
INTRODUCTION
Reduced miR-133a is associated with thoracic aortic (TA) dilation as seen
in aneurysm disease. Since wall tension increases with vessel diameter (Law of
Laplace), this study tested the hypothesis that hypertension results in the
reduction of miR-133a in the TA. While, hypertension has been
epidemiologically associated with aortic pathologies, such as thoracic aortic
aneurysm(302), a biochemical relationship between increased wall tension and
aortic remodeling has yet to be identified.
The previous in vitro studies have identified that mechanical tension is a
stimulus driving the reduction of miR-133a in thoracic aortic fibroblasts via
exosome secretion. While these data provided insights into a mechanism
involved in this process, it remained to be determined whether these results
could be recapitulated in vivo. Accordingly, the following studies utilize distinct
murine models of hypertension for the further analysis of the effect of a
physiologically relevant level of increased aortic wall tension on miR-133a levels.
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Of significant relevance, detectable levels of circulating microRNAs are
becoming a topic of increased interest.(303) Since the initial observation of
circulating microRNAs in 2008, it has been suggested that their presence may
serve as a possible biomarker for prognostic and diagnostic purposes related to
the presence of cardiovascular disease. Furthermore, various pathological
conditions have been shown to be associated with altered microRNA profiles in
plasma. Importantly, this laboratory reported elevated plasma miR-133a levels
associated with thoracic aortic aneurysm.(213) This study demonstrated that it
was indeed possible to measure an analyte directly relevant to vascular
remodeling in the plasma. While other analyte signatures were combined to
most accurately predict the presence of an aortic aneurysm, miR-133a alone had
significant specificity. It remained to be determined if elevated vessel wall
tension was sufficient in altering circulating miR-133a levels.
In the following studies, increased vessel wall tension will be simulated in
vivo utilizing two unique murine models of hypertension. As a potent vasoactive
peptide, Angiotensin II (AngII) contributes to vasoconstriction to increase
vascular wall tension (Discussed in Chapter 2); therefore, the first model of
hypertension was induced in vivo utilizing a well-established AngII infusion
model.(80, 236, 304) The second murine model of hypertension, is a
commercially available hypertensive mouse that has been genetically selected
(BPH2). In this mouse model, it has been demonstrated that hypertension is not
the result of increased circulating levels of angiotensin, allowing for the
comparison of two distinctly different causes of elevated tension. Accordingly,
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the effects of tension will be examined on the TA tissue and plasma levels of
miR-133a.

RESULTS
Increased vessel wall tension in vivo results in a reduction of thoracic
aortic tissue miR-133a abundance.
Murine Blood Pressure
Two distinct murine models of hypertension were utilized to examine the
effects of elevated aortic wall tension on miR-133a abundance in vivo. To
demonstrate relative changes in mean arterial pressures (MAP), murine blood
pressure measurements were obtained by tail-cuff using the CODA
hemodynamic monitoring system from Kent Scientific. Mean arterial pressure in
wild-type normotensive mice was determined to be 121.16±2.59 mmHg
(normotensive, n=12). Normotensive mice were treated with Angiotensin-II
(AngII, 1.44mg/kg/day) delivered by subcutaneous osmotic pump for 28
days.(305) This resulted in an increased MAP to 169.94±3.50 mmHg (AngII,
n=12) (p<0.05 vs. normotensive) (Figure 4.1, and Table 4.1). Second, the effects
of elevated wall tension on miR-133a abundance were examined in a
spontaneously hypertensive mouse line (BPH2, genetically selected, angiotensin
II-independent),(306) which displayed an elevated MAP of 159.67±2.97 mmHg
(BPH2; p<0.05 vs normotensive, n=12) (Table 4.1 and Figure 4.1).
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Table 4.1. Murine blood pressure. Data are presented as mean and standard
deviation of the systolic, diastolic and calculated mean arterial pressure (MAP) as
determined by non-invasive tail cuff measurements in the three groups of mice
utilized in these studies.

Figure 4.1. Mean arterial blood pressure and miR-133a levels in thoracic
aortic tissue and plasma from two murine models of hypertension. Mean
arterial blood pressure assessed by non-invasive tail cuff, in control mice (Control,
n=12), Ang II-induced hypertensive mice (AngII, n=12), and spontaneously
hypertensive mice (BPH2, n=12). Data are represented as mean ± SEM.
Comparisons were made using a one-way ANOVA followed by pairwise
comparison of means by Tukey’s wholly significant difference (wsd) method. * p <
0.05 vs control.
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Murine tissue and plasma miR-133a levels
The thoracic aortic tissue abundance of miR-133a was reduced in both the
AngII-treated and the BPH2 mice when compared to normotensive controls
(AngII: 0.69±0.06 fold, n=12, p<0.05 vs control; BPH2: 0.52±0.04 fold, n=16,
p<0.05 vs control; control: 1.00±0.13, n=12) (Figure 6B). Plasma levels of miR133a were assessed in both hypertensive mouse models. While miR-133a
abundance was elevated in the plasma of the AngII-induced mice, they failed to
reach statistical significance (1.80±0.64 fold, n=6, p=ns). However, miR-133a
levels were significantly increased in the plasma of BPH2 mice (3.39±0.77 fold,
n=8, p<0.05) as compared to normotensive control animals (1.0±0.41, n=6)
(Figure 6C). Combined, these results demonstrated that miR-133a abundance is
reduced in thoracic aortic tissue in response to elevated vessel wall tension.
Moreover, circulating plasma levels of miR-133a were increased.
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Figure 4.2 miR-133a levels in thoracic aortic tissue and plasma from two
murine models of hypertension. (A) miR-133a abundance in thoracic aortic
tissue from control mice (Control, n=12), Ang II-induced hypertensive mice (AngII,
n=12), and spontaneously hypertensive mice (BPH2, n=16). (B) Plasma miR-133a
abundance in control mice (Control, n=6), Ang II-induced hypertensive mice (AngII,
n=6), and spontaneously hypertensive mice (BPH2, n=8). Data are represented
as mean ± SEM. Comparisons were made using a one-way ANOVA followed by
pairwise comparison of means by Tukey’s wholly significant difference (wsd)
method. * p < 0.05 vs control.
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Circulating miR-133a abundance was increased in hypertensive patients.
The abundance of miR-133a was determined in plasma samples collected
from patients previously diagnosed with hypertension and compared to
normotensive controls (patient demographical information listed in Table 4.2).
Blood pressure was measured at the time of blood draw, and the calculated MAP
was determined to be elevated in the hypertensive patients as compared to a
normotensive control group of patients never diagnosed with hypertension
(97±6mmHg, n=11 vs 89±8mmHg, p<0.05, n=12) (Figure 4.3) (blood pressures
listed in Table 4.2). Furthermore, circulating plasma levels of miR-133a were
increased in the hypertensive group when compared to normotensive controls
(1.55±0.26, n=11 vs 1.0±0.18 fold; p<0.05, n=12) (Figure 4.4). These results
demonstrated that increased MAP resulted in elevated plasma levels of miR133a.
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Normotensive (n=12) Hypertensive (n=11)
Gender: male (%)
25
27
African American (%)
8
27
Age (years)
63±4
65±3
Heart Rate (BPM)
68±9
70±12
2
Body Surface Area (m )
1.76±0.26
2.03±0.18
Walk in 6 minutes (m)
396.8±51.4
386.6±45.3
Systolic Blood Pressure (mmHg)
122±9
131±9
Diastolic Blood Pressure (mmHg)
72±8
80±6
Mean Arterial Pressure (mmHg)
89±8
97±6

p-value
0.901
0.231
0.193
0.654
0.009
0.620
0.026
0.014
0.014

Table 4.2. Patent demographics. Demograpical information of patents included
in these studies. Data are presented as a mean ± standard deviation. A Chi 2
analysis was performed on gender and ethnicities. For all other categories
pairwise comparisons were made using two sample t-tests. All p-values are
displayed.

Figure 4.3. Mean arterial blood pressures. Patient mean arterial blood pressures
assessed at time of plasma collection in Normotensive (n=12) and Hypertensive
(n=11) patients. Data are represented as mean ± SEM. Comparisons were made
using a two-sample t-test (unpaired, two-tailed). * p<0.05 vs. control.
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Figure 4.4. Plasma levels of miR-133a in clinical specimens. Plasma miR133a abundance in normotensive (n=12) and hypertensive (n=11) patients. Data
are represented as mean ± SEM. Comparisons were made using a two-sample ttest (unpaired, two-tailed). * p<0.05 vs. control.
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SUMMARY
Two distinct murine models of hypertension were utilized to simulate
increased aortic wall tension in vivo. In both murine models, elevated mean
arterial blood pressures were confirmed and miR-133a was found to be reduced
in thoracic aortic tissue. Circulating miR-133a was increased in the plasma of
the BPH2 hypertensive mice. Finally, in clinical plasma samples from
hypertensive patients, circulating miR-133a was elevated when compared to the
non-hypertensive control group.

DISCUSSION
In order to examine the physiological relevance of the effects of
mechanical tension on miR-133a levels, a clinically relevant form of increased
vessel wall tension in vivo were examined on the aortic tissue levels of miR133a. For this approach, two unique murine models of hypertension were
utilized. As a potent vasoactive peptide, AngII contributes to vasoconstriction to
alter vascular wall tension; accordingly in the first in vivo model, hypertension
was induced by delivering AngII by osmotic pump infusion.(80, 236, 304) The
second in vivo model of increased wall tension is a commercially available,
hypertensive mouse line (BPH2). In this murine hypertensive model, it has been
reported that hypertension is angiotensin-independent, through the observation
of low circulating angiotensin-I levels in these mice.(307) In both murine models,
elevated mean arterial blood pressures were confirmed compared to wild-type
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mice and as anticipated, miR-133a was found to be reduced in the tissue of the
descending thoracic aorta. In a similar study performed by Castoldi and
colleagues, hypertension was induced in Sprague-Dawley rats by treatment with
AngII via implanted osmotic pump. Following 4 weeks of induced hypertension,
the levels of miR-133a were assessed in myocardial tissue and in similar fashion,
miR-133a abundance was reduced. While Castoldi and colleagues were able to
inhibit the loss of miR-133a with an AngII receptor blocker, irbesartan, they were
unable to determine whether this effect was mediated, entirely or in part, by AngII
signaling or by elevated mechanical tension.(221) Our study examined the effect
of biaxial cyclic stretch on isolated aortic cells (fibroblasts and SMCs) in the
absence or presence of AngII, and demonstrated that the effects of mechanical
tension were fibroblast-specific and independent of AngII stimulation.
Accordingly, when we examined these effects in vivo we were not surprised that
miR-133a was reduced in the thoracic aorta of both the AngII -dependent and independent models of hypertension. Moreover, both models of murine
hypertension displayed increased plasma levels of miR-133a. While statistical
significance was reached only in the BPH2 model, this may have been due to the
time difference in exposure to elevated blood pressures. Whereas the AngII
model of hypertension was initiated when the animals were 10 weeks of age, and
allowed to continue for 4 weeks, the spontaneously hypertensive BPH2 mice
were 12-14 weeks of age when examined, and had likely experienced elevated
blood pressure since 5 weeks of age.(308) Nevertheless, in both murine models
of hypertension, miR-133a was reduced in TA tissue, and this finding was
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associated with increased circulating levels of miR-133a, demonstrating tension
has a profound effect on the levels of this mechanically sensitive miR.
Taken together, these findings led us to the question of whether this effect
could be observed in hypertensive patients. Accordingly, miR-133a was
measured in the plasma of patients that had documented hypertension and left
ventricular hypertrophy. The results of this study demonstrated that plasma levels
of miR-133a were increased in hypertensive patients when compared to a
normotensive group. Our results were supported by previous findings
demonstrating increased circulating levels of miR-133a in patients with unstable
angina pectoris, takotsubo cardiomyopathy, acute myocardial infarction,(309)
and thoracic aortic aneurysm,(213) suggesting that elevated circulating levels of
miR-133a are associated with the presence of cardiovascular disease. While
hypertension is a known risk factor for many cardiovascular disease states, the
molecular mechanisms involved in this relationship remain poorly understood,
and the current findings may provide a valuable link.
Following transcription and subsequent processing, mature microRNAs
are incorporated into the RNA-induced silencing complex, which directs the
microRNA to the target mRNA,(310) resulting most commonly in translational
repression.(237) Therefore, reduction in miR abundance would permit elevated
protein translation of the targeted gene transcripts. A role of miR-133a in
mediating matrix production has been demonstrated in cultured fibroblasts
through the targeted repression of the TGF-β and TGF-βRII signaling cascade
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that promotes production and deposition of collagens related to the development
of fibrosis.(219) Furthermore, there is increasing evidence that miR-133a may
play a role in the determination of cellular phenotype, such as proliferation and
migration,(222, 311) and it is known that miR-133a levels alter key proteins which
are highly expressed in the tissue associated with adverse aortic remodeling.
For example, miR-133a directly targets and reduces the abundance of the
membrane type-1 matrix metalloproteinase (MT1-MMP).(222, 243) This
membrane bound proteolytic enzyme is known to contribute to both degenerative
extracellular matrix remodeling, as well as matrix production through the
activation of the TGF-β pathway.(192) Furthermore, using MT1-MMP
overexpressor and knockout mice, Spinale and colleagues demonstrated that
MT1-MMP is a direct effector of cardiac fibrosis.(312) Moreover, it has been
demonstrated that MT1-MMP is elevated throughout thoracic aortic aneurysm
development in both clinical specimens (186, 192) and mouse models of
TAA.(188, 192) While the direct effects of tension-induced changes in miR-133a
abundance, and its effect on adverse aortic remodeling remains to be defined,
these current findings highlight the importance in managing elevated blood
pressure, and may lead to the development of novel pharmacotherapies directed
at inhibiting the secretion of miR-133a from aortic fibroblasts.
LIMITATIONS
The present study is not without limitations. First, murine blood pressures
were assessed using a non-invasive tail cuff system. This system routinely
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reports systolic and diastolic pressures that contribute to a normotensive MAP of
approximately 120 mmHg in the untreated wild-type control mice. While a MAP
of this value would typically be considered hypertensive, these results are
consistent with other investigators utilizing the CODA system for measuring
murine blood pressure.(313, 314) Therefore, we assessed the relative difference
between the groups of mice, and were able to determine a significant increase in
the blood pressure measurements in both experimental models of elevated wall
tension when compared to the normotensive controls. Second, while circulating
levels of miR-133a were identified to be elevated in clinical plasma samples
taken from hypertensive patients, the sample size of measurements was limited
therefore caution should be exercised in data interpretation. Further studies
must be undertaken in a larger number of samples to determine whether there is
a linear correlation between pressure and miR-133a abundance. Lastly, it is
important to note that all of the hypertensive patients in this study were actively
being treated with anti-hypertensive agents at the time their blood was collected.
In spite of this, their blood pressures, as well as their plasma levels of miR-133a,
were still significantly elevated as compared to the non-hypertensive control
group. This may suggest that the amount of wall tension associated with the
current suggested therapeutic blood pressure target is still sufficiently high to
result in the elevated release of miR-133a. Furthermore, circulating miR-133a
levels may be used to better refine therapeutic blood pressure control. Additional
studies examining its use in this regard are warranted.
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CONCLUTIONS
By investigating the tension-induced reduction of miR-133a, the current
studies identified hypertension as a stimulus driving the loss of mature miR-133a
in thoracic aortic tissue. These data lend support to the hypothesis that as blood
pressure increases, tension on the aortic wall increases, and cellular miR-133a
abundance is reduced in fibroblasts via exosome secretion. This may have
significant implications regarding early aortic wall remodeling in response to
uncontrolled hypertension. Taken together, the results of this set of
investigations have identified a specific tension-sensitive mechanism by which
miR-133a was reduced in thoracic aortic tissue, and elevated in plasma. These
data hold significance with regard to the potential advancement in understanding
the role of miR-133a in the regulation of adverse thoracic aortic remodeling.
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CHAPTER 5: Conclusions and Clinical
Significance
The results presented in the body of this work demonstrated that
increased tension results in the loss of miR-133a from aortic fibroblasts by a
mechanism involving exosome secretion. Furthermore, results demonstrate that
miR-133a levels are reduced in the thoracic aortas of mice with increased vessel
wall tension, and that increased circulating levels of miR-133a were detected in
hypertensive mice. This observation has clinical relevance since miR-133a was
also found to be elevated in the plasma of hypertensive patients. This study is
the first to document increased vessel wall tension as a stimulus through which
miR-133a is reduced in thoracic aortic tissue.
Following transcription and subsequent maturation, mature microRNAs
are incorporated into the RNA-induced silencing complex, which directs the
microRNA to the target mRNA,(310) resulting most commonly in translational
repression.(237) Loss in mature microRNA abundance would allow for increased
translation of targeted gene transcripts. There is increasing evidence that miR133a plays a role in the determination of cellular phenotype, such as proliferation
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and migration,(222, 311) and it is known that miR-133a levels alter key proteins
which are highly expressed in the tissue associated with adverse aortic
remodeling. For example, miR-133a directly targets the membrane type-1 matrix
metalloproteinase (MT1-MMP).(222, 243) This proteolytic enzyme is known to
contribute to degenerative extracellular matrix remodeling and is elevated
throughout TAA development in clinical specimens (186) and mouse models of
TAA.(188) Furthermore, miR-133a has been demonstrated to regulate vascular
remodeling in vivo,(214) which underscores the significance in identification of
regulatory mechanisms.
A previous report demonstrated vessel wall tension affects gene
expression profiles of several matrix metalloproteinases in thoracic aortic tissue
through the induction of promoter activity.(235) The present study built upon
these previous findings by demonstrating an alternative pathway affected by
mechanical tension. This report is the first to identify that increased tension
alone affects the abundance of mature miR-133a in thoracic aortic tissue.
Further exploration of the two major cell types of the aorta identified that biaxial
cyclic stretch led to the reduction of miR-133a from fibroblasts while SMCs were
not responsive. Interestingly, in another study, mechanical stretch was
demonstrated to not have an effect on the level of miR-133a.(315) Combined
with the results from this study, stretch induced reduction of miR-133a appears to
be cell type specific.
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Fibroblasts have been identified as a cell type that is sensitive to
mechanical tension and subject to undergo changes, taking on “synthetic” or
mobile characteristics. Once altered, these fibroblasts become known as
myofibroblasts. In pathological vascular remodeling, these synthetic fibroblasts
become activated in the adventitia, and migrate inward disrupting the
extracellular matrix and increase vessel stiffness.(167) Combined with previous
studies which have demonstrated aortic dilation is accompanied by the apoptotic
loss of SMCs,(248) it is believed that the fibroblasts may be a key cellular
mediator contributing to aortic remodeling.(195) Of significant relevance, a single
microRNA is capable of targeting multiple mRNAs; therefore, alterations in the
abundance of one microRNA may result in changes of multiple targeted proteins.
Therefore, tension induced loss of miR-133a from fibroblasts may predispose
patients to adverse thoracic aortic remodeling.
While hypertension is a known risk factor for aortic dilation and aneurysm
formation, the molecular mechanisms involved in this relationship remain poorly
understood. Not only do patients diagnosed with essential hypertension have
high circulating levels of AngII,(246) it is also a known vasoconstrictor, therefore
the effects of this vasoactive peptide was investigated on miR-133a levels. By
mounting aortic rings on parallel wires in an ex vivo tissue myograph and adding
AngII, it was determined that AngII induced vessel contraction resulting in
elevated wall tension and a loss of miR-133a. Importantly, when investigations
continued by proceeding to in vitro AngII stimulation of isolated fibroblasts and
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SMCs, no effect on miR-133a abundance was detected. These findings led to
the conclusion that the AngII effects on miR-133a in aortic tissue was not due to
AngII receptor mediated signaling, but was likely the result of vessel contraction,
leading to increasing tension on the endogenous fibroblasts.
To identify if transcriptional regulatory mechanisms of mature miR-133a
were altered with mechanical tension, primary (pri-) miR-133a transcript levels
were assessed. Production of microRNAs begins with the synthesis of primicroRNAs.(203) A reduction in mature microRNA abundance resulting from a
decrease in transcription would be observed by the detection of reduced primary
microRNA transcript levels. Although mechanical tension had no effect on primiR-133a-1 levels, tension appeared to increase pri-miR-133a-2 levels,
suggesting an increase in transcription with tension application. Combined with
the observation of decreased mature miR-133a abundance, this association may
suggest mechanical tension could lead to other defects in miR-133a processing,
to be examined in future investigations.
Other cellular mechanisms leading to decreased mature microRNA levels
include degradation by microRNA specific ribonucleases. Mature microRNAs
have 5’ and 3’ unprotected ends that render them accessible to specific
ribonucleases. Three known microRNA specific ribonucleases have been
identified (XRN-1, XRN-2, and ExoSC4).(253, 256) Therefore, the effects of
mechanical tension on these 3 ribonucleases were examined. While the mRNA
expression and protein abundance remained unchanged for the ribonucleases,
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other mechanisms of activation, for example phosphorylation, were not
investigated. While it is unclear whether mechanisms of activation of XRN1,
XRN2 or ExoSC4 may play a role in determining mature microRNA abundance,
investigations in alternative pathways may warrant future investigations.
There is growing evidence focusing on the significance of microRNA export
via extracellular vesicles.(283) Therefore, the effect of mechanical tension on
extracellular vesicle secretion of miR-133a was examined in isolated aortic
fibroblasts. The activity of acetylcholine esterase, which is enriched in the
plasma membrane of extracellular vesicles, was demonstrated to be increased in
the precipitated extracellular vesicles from the media of fibroblasts exposed to
cyclic stretch. This finding may suggest either an increase in extracellular vesicle
number or an increase in size. Nevertheless, more miR-133a was detected in
the extracellular vesicles collected from the media of fibroblasts exposed to
stretch. Increasing evidence suggests microRNAs are not randomly incorporated
into extracellular vesicles,(284-286) and another report has indicated that
microRNA abundance within these vesicles is altered in pathology.(287) In
agreement with these previous studies, the present results suggest miR-133a
may be preferentially incorporated into exosomes and secreted from fibroblasts
exposed to stretch.
Cargo sorting mechanisms of exosomes are far better understood than
that of microvesicles, and one mechanism regulating the secretion of exosomes
is an nSMase2-dependent pathway.(262) The effect of inhibiting nSMAse2 with
114

the use of GW4869 (hydrochloride hydrate) prevented tension induced reduction
of miR-133a from fibroblasts, confirming that the nSMase2-dependent pathway is
responsible for mediating secretion of exosomes containing miR-133a.
Investigations continued by examining a clinically relevant form of
increased vessel wall tension on miR-133a levels in vivo. For this, two unique
murine models of hypertension were utilized. As a potent vasoactive peptide,
AngII contributes to vasoconstriction to alter vascular wall tension; therefore, in
the first model, hypertension was induced in vivo utilizing a well-established AngII
infusion model.(80, 236, 304) The second in vivo model of increased wall tension
is a commercially available, hypertensive mouse line (BPH2). In this murine
hypertensive model, it has been reported that hypertension is angiotensinindependent, through the observation of low circulating angiotensin I levels in
these mice.(14) In both murine models, elevated mean arterial blood pressures
were confirmed and miR-133a was found to be reduced in the thoracic aorta.
While circulating levels of miR-133a were increased in the plasma of both
hypertensive mouse models, the levels in the BPH2 mice were the only to reach
statistical significance by a one-way analysis of variance (ANOVA) followed by
pairwise comparison using Tukey’s method. This may be due to the comparison
of an acute model of hypertension (AngII for 28 days) to a chronic hypertensive
model (BPH2), and future studies investigating a longer delivery of AngII may
provide interesting answers to the role of elevated tension on circulating levels of
miR-133a.
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Access to thoracic aortic tissue from hypertensive patients may provide
further understanding; however, these studies were able to identify circulating
miR-133a abundance in hypertensive patient plasma. While the individuals
diagnosed with hypertension were being treated with anti-hypertensives at the
time of blood draw, assessment of mean arterial blood pressure was identified to
be significantly elevated when compared to the normotensive group. Most
interestingly, patients with increased MAP had elevated plasma levels of miR133a, supporting the notion that increased tension results in increased circulating
miR-133a levels.
The risk of cardiovascular disease is higher in those with elevated blood
pressures, and this could potentially be one of the many contributing factors.
While the direct effects of tension induced alterations in miR-133a abundance
has on adverse aortic remodeling remains to be determined; however, these
findings highlight the importance in managing elevated blood pressure and may
lead to the novel development of pharmacotherapies directed at inhibiting the
secretion of miR-133a from aortic fibroblasts.
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CHAPTER 6: Future Directions
The following chapter will provide preliminary data and rationale for future
studies. This section will focus on applying the major findings presented in the
previous chapters to future investigations in the regulation of thoracic aortic
aneurysm (TAA) formation and progression. As demonstrated, increased
mechanical tension results in the reduction of miR-133a from thoracic aortic
fibroblasts, however it remains to be determined what effects this has on cellular
phenotype and aortic pathologies, such as thoracic aortic aneurysm formation.
Accordingly, the following studies will: 1) determine the role of miR-133a in
mediating in vitro phenotypes, via overexpression and knockdown in primary
aortic fibroblasts isolated from a murine model in which TAA has or has not been
induced; and 2) explore whether viral-mediated miR-133a replacement
attenuates the development of TAA in an establish murine model.
Thoracic aortic aneurysm (TAA) is a localized dilation of the
supradiaphragmatic aorta. This devastating disease process is often
asymptomatic and results in a weakened aortic wall and can progress to rupture
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if left untreated;(29) however, the underlying molecular mechanisms leading to
the development of TAA are largely unknown. While there are numerous
etiologies that contribute to the manifestation of TAA, abnormal remodeling of the
aortic extracellular matrix (ECM) and changes in the resident cellular population
universally occur.
Histological examination of aortic structure and composition has
demonstrated a decline in the smooth muscle cell population coinciding with an
emergence of fibroblast derived myofibroblasts.(94) It is believed this population
of fibroblasts plays a key role in managing the remodeling process through the
observed association with elastic fiber and medial degeneration.(63, 94, 168)
Interestingly, it has been demonstrated that isolated primary aortic fibroblasts
from TAA tissue sustain a stable alteration in gene expression profile;(195)
however, it remained to be determined the effects this has on cellular function.
Under normotensive conditions, a physiologically relevant level of wall
tension is essential for maintaining normal vessel structure.(223) As discussed in
previous chapters, wall tension is directly related to the radius of the vessel and
intraluminal pressure, thus, when blood pressure is constant and vessel dilation
occurs, wall tension rises. Interestingly, an alteration in the amount of tension
placed on cells has been demonstrated to modulate complex phenotypes, such
as proliferation, migration, and adhesion.(224-228) Previous results in this body
of work have demonstrated tension reduces miR-133a in aortic fibroblasts. As,
the importance of miR-133a in the regulation of ECM remodeling in
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cardiovascular disease is becoming increasingly recognized, it would be highly
interesting to determine if miR-133a alone has an effect on cellular phenotype.
While there are numerous etiologies contributing to the manifestation of
TAA, abnormal remodeling of the vascular ECM universally occurs. ECM refers
to the collagen and elastin cytoskeleton surrounding the cells which contain
sequestered growth factors and cytokines. The ECM provides structural and
biochemical support to the resident cells, of which remodeling is an important
process in regulating the dynamic balance between degradation and deposition,
in which a critical family of proteolytic enzymes, the matrix metalloproteinases
(MMPs), actively participate through the degradation of all ECM components and
subsequent release of sequestered growth factors and cytokines (123, 142).
Previous results determined that increased vascular wall tension results in
the reduction of miR-133a in thoracic aortic fibroblasts via exosome secretion. As
aortic diameter increases during the aortic dilation in TAA, wall tension rises
proportionally. As discussed in Chapter 1, this laboratory has demonstrated that
miR-133a is reduced in TAA tissue with increasing diameter.(212) Combined,
these findings suggest that loss of miR-133a-mediated translational control of
specific gene targets may contribute to TAA formation and progression.
To study the molecular mechanisms responsible for the development and
progression of TAA, this laboratory has developed and validated a surgical model
of TAA in mice.(82, 91, 92, 115, 134, 169, 195, 316, 317) Murine TAA may be
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induced via CaCl2-soaked sponge (0.5 M) placed in direct contact with the
periadventitial surface of the descending thoracic aorta and kept in place for 15
minutes. This method results in the reproducible dilatation of the thoracic aorta
over a prolonged period of time.(82) While the inciting stimulus of TAA formation
remains undefined, it has become clear that TAA is not the result of an acute
chemical injury, but a process that is initiated and slowly progresses. Importantly,
early examination of aortic tissue sections following CaCl2 exposure revealed
normal aortic structure and the absence of inflammatory infiltrate; TAA tissue
stained for macrophages, neutrophils, T-cells, and B-cells revealed little change
from untreated control aortic sections.
This laboratory has now extensively characterized this mouse model of TAA
and has published multiple peer-reviewed manuscripts describing mechanisms
related to TAA development that not only recapitulate the structural hallmarks of
human TAA, but also replicate the changes in cellular content, the modifications in
biochemical mediators, and the altered intracellular signaling consistent with what
is observed in human clinical specimens.
It must be recognized, there is no singular animal model, in large or small
animals that perfectly replicates human aneurysms on a temporal and molecular
scale; however, the similarities observed between murine and human TAAs,
provide validation that this murine TAA model replicates many of the key hallmarks
of human TAA pathophysiology. Therefore, this model provides a suitable test bed
for the completion of the following future studies.
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To confirm miR-133a is reduced in murine TAA tissue, TAA was induced
as described. Following 3 weeks of aneurysm formation aortic diameter was
assessed and found to be significantly increased (Figure 6.1) and the aortic
tissue was harvested. Total RNA was isolated and miR-133a was quantitated as
previously described. The aortic tissue abundance of miR-133a was reduced in
TAA when compared to control (Figure 6.2).
Combined, the previous results from clinical specimens and this calcium
chloride induced murine model of TAA demonstrate a reduction of miR-133a as a
function of increased aortic diameter. Furthermore, aortic fibroblasts have been
demonstrated by PCR array to undergo a stable phenotypic change in gene
expression profiles during the development of TAA, (195) which is believed to
drive the enhancement of extracellular matrix proteolysis in TAA development.
Therefore, the directions of these investigations will aim to first define the
phenotypic alterations in TAA fibroblasts, then progress these findings by
determining if miR-133a is a regulator of the phonotype observed.
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Figure 6.1 Murine model of TAA. Aortic diameter measurements obtained by
calibrated video microscopy a baseline and 3 weeks following the induction of TAA
(Terminal) (n=6). An unpaired comparison was made using a two sample t-test. *
p < 0.05 vs control.

Figure 6.2 miR-133a abundance in TAA tissue. miR-133a abundance in aortic
tissue from unoperated (Referent Control) and 3 weeks following induction of TAA
(Terminal) (n=6). An unpaired comparison was made using a two sample t-test. *
p < 0.05 vs control.
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The role of miR-133a in mediating in vitro phenotypes
Phenotype is the composite of the observable characteristics of a cell.
Many factors contribute to the determination of overall cellular phenotype. Due
to the complexities of the pathways involved, multiparameter approaches
allowing for the quantitation of overall effect are best suited for the observation of
alterations in these phenotypes. In the following studies the parameters of
proliferation, migration, and adhesion were selected to observe overall alterations
in cellular phenotype. Proliferation of cells is an important process resulting in
increased cell number, and can be defined as the balance between cellular
division and death. Cellular migration is regulated largely by the cells ability to
interact with the extracellular matrix, a process involving matrix metalloproteinase
production. Furthermore, it has been demonstrated that mechanotransduction
alone is sufficient in the regulation of cellular proliferation and migration.(318)
Overall differences in the adhesive properties of a cell may be determined by
allowing a cell to bind to a substrate, and non-bound cells are then removed by
gentle washing. The remaining adherent cells are quantitated, allowing for the
estimation of alterations in the ability to for interactions with the extracellular
matrix, which is necessary for the ability to migrate. Therefore, assessment of
overall cellular function will be described in the following sections.
Primary cultures of aortic fibroblasts were established and maintained in
cell type specific media using a well-recognized outgrowth technique.(243, 319,
320) First, the cellular abundance of miR-133a was compared between control
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and TAA fibroblasts (Figure 6.3). As expected, these data demonstrate miR133a abundance is significantly reduced in TAA fibroblasts as compared to
control. Further alterations in phenotype in vitro may be quantified utilizing
specific endpoints such as proliferation, migration, and adhesion. Therefore, the
following studies will compare these endpoints in fibroblasts isolated from control
and TAA. As a pilot study, the TAA fibroblasts were treated with 100nM of miR133a oligo via lipofectamine transduction following manufacturer’s instructions
and then assayed.
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Figure 6.3 Aortic fibroblast miR-133a abundance. miR-133a abundance in
cultured aortic fibroblasts isolated from unoperated (Control) and TAA mice (n=6).
An unpaired comparison was made using a two sample t-test. * p < 0.05 vs control.

Proliferation was determined as follows. Cells were seeded at 1,000 cells
per well of a 96 well clear bottom plate (Costar Flat bottom Cell bind Surface
[Poly-D-Lysine] Cat# 3300, Corning, NY), and allowed to adhere overnight. The
following day growth media was aspirated and replaced with fresh complete
media. CyQuant Direct Cell Proliferation Assay (Cat#C35011, Molecular probes)
kit was then used to determine percent change in cell number from baseline.
The basis of the CyQUANT kit is the use of a green fluorescent dye, which
exhibits strong fluorescence enhancement when bound to cellular nucleic acids.
This kit was allowed to equilibrate to room temperature and the following will be
mixed: PBS (97.5%), Cyquant Direct nucleic acid stain (0.004%), and direct
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background suppressor (0.02%). 12 hours following the addition of fresh
complete phenol-free fibroblast growth media, an equal volume of 2X Detection
reagent was added to the cells in the culture media (assay is compatible in media
with or without serum). Cells were then incubated for 1 hour at 37°C with 5%
CO2. Following one hour incubation time, fluorescence was read from the
bottom of the well at 480/535 Ex/Em. This was then repeated at 24, 48, and 72
hours. Proliferation results in Figure 6.4 demonstrated that the percent change
from baseline of aortic fibroblasts derived from murine TAA is increased as
compared to non-TAA controls, and when TAA fibroblasts are treated with
100nM of miR-133a oligo, percent change in proliferation is significantly reduced
and returned to within control range. These preliminary data demonstrate that
miR-133a alone affects proliferation, and may return TAA fibroblast rate of
proliferation to within normal limits.
To compare migration properties between control and TAA, fibroblasts
were treated with Mytomycin C (Sigma-Aldrich; Cat# M0503) (8ug/mL) for 1 hour
to inhibit proliferation, then rinsed twice with PBS and fresh complete fibroblast
growth media was added and the cells were returned to standard tissue culture
conditions for 24 hours. The following day the fibroblasts were lifted using a
PBS-based enzyme free cell dissociation buffer. 2.5x10^4 cells were seeded in
serum free medium and allowed to adhere on the top surface of an 8uM porous
membrane overnight. Complete media was then added to the bottom portion of
the boyden chamber and the cells were allowed to migrate through the porous
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membrane for 48 hours. Results from the migration assay in Figure 6.5
demonstrate that the motility of TAA fibroblasts was increased, and when treated
with exogenous miR-133a, migration was reduced toward that of the control.
Adhesion is an important and complex cellular phenotype that involves
multiple molecular interactions, including receptor to ligand binding of the cell
surface and extracellular matrix, as well as modulation in the assembly of the
cytoskeleton. Consequently, the adhesive properties of a cell are informative in
not only the measurement of the contacts between the cell and extracellular
matrix, but also the state of the cell. Therefore, aortic fibroblast phenotype was
assessed by seeding 2,000 cells per well in 100 uL of complete growth media per
well of a 96 well clear bottom plate (Costar Flat bottom Cell bind Surface [Poly-DLysine] Cat #3300, Corning, NY). Cells were then allowed to adhere by returning
the plate to the incubator for 1 hour in standard tissue culture conditions. The
plate was then washed five times with room temperature PBS (with Ca2+/Mg2+)
using a BioPlex Pro Plate Washing Station set to “Drip Fill” to achieve
consistency in washes across plates. Each well was then carefully aspirated so
as to not disturb the cells, and 100 uL of complete, phenol-free fibroblast growth
media was added to the cells. Cells were then fluorescently labeled, and relative
fluorescence was quantitated by microplate reader. Results demonstrate that
TAA fibroblasts have reduced adhesion as compared to control, and when
treated with exogenous miR-133a, surpass the adhesive property of the control
fibroblasts (Figure 6.6).
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It is apparent that the phenotypic properties of TAA fibroblasts in respect
to proliferation, migration, and adhesion are significantly altered and this cell
population takes on classic characteristics of a more motile and proliferative
myofibroblast. Most interestingly, these preliminary studies suggest miR-133a
has the profound ability to regulate these aspects of cellular phenotype, shifting
properties back toward normal fibroblast characteristics.
More than a simple increase in sample size is required for the resolution of
these studies (Goal: n=8 as determined by power analysis, α=0.05, β=0.20).
Inclusion of proper controls in this examination is key for completion. The use of
a non-mammalian targeting microRNA such as cel-miR-39 would provide
valuable insight accounting for any effects of transduction by lipofectimine.
Furthermore miR-1, which is included in the same two bicistronic units within the
genome as miR-133a, and demonstrated by Torella et al. to not have the same
protective capacity as miR-133a in the prevention of adverse vascular
remodeling,(214) would be a highly interesting prospect for use as a control
microRNA for these studies. Furthermore, knockdown of miR-133a with the use
of an Anti-miR-133a would provide further evidence in the control of cellular
phenotype. An Anti-microRNA is a single stranded oligo that competitively binds
to a targeted microRNA, inhibiting interaction with mRNA. Therefore, treatment of
control fibroblasts with the anti-miR-133a may result in a TAA fibroblast
phenotype.
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In addition to proper controls, I propose to strengthen the study through
the inclusion of an investigation in the effects of miR-133a on several gene
expression and protein markers of the fibroblast to myofibroblast transition.
Fibroblasts may be identified through the expression of the discoidin domaincontaining receptor 2 (DDR2). This protein is a collagen receptor that has
previously been shown to display fibroblast restricted expression, and has been
demonstrated in cardiovascular tissue to be a superior marker for fibroblasts than
even the fibroblast specific protein-1.(95) Myofibroblasts may be identified
through the positive expression for DDR2 and smooth muscle myosin heavy
chain (MYH11), and α smooth muscle actin (αSMA).(94)
Based on bioinformatics analysis it does not appear that miR-133a directly
targets either of these markers; however, it is our belief that reduction of miR133a may result in the over expression of a program of genes that may influence
the fibroblast to myofibroblast transition. As the myofibroblast has been identified
as a critical cell type capable of modulating the ECM remodeling process, the
effects of miR-133a on modulation of this phenotype would provide valuable
insight in the regulation of TAA development.
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Figure 6.4 Aortic fibroblast proliferation. Percent change in cultured aortic
fibroblast proliferation from Control and TAA fibroblasts.

In addition, TAA

fibroblasts were treated with exogenous miR-133a in culture (TAA+miR-133a)
(n=4). * p < 0.05 vs control value at the respective time point. # p<0.05 vs TAA at
the respective time point.

Figure 6.5 Aortic fibroblast migration. Number of migrated Control and TAA
fibroblasts. In addition, TAA fibroblasts were treated with exogenous miR-133a in
culture (TAA+miR-133a) then allowed to migrate (n=4). * p < 0.05 vs control. #
p<0.05 vs TAA.
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Figure 6.6 Aortic fibroblast adhesion. Fluorescently labeled Control, TAA, and
TAA fibroblasts treated with exogenous miR-133a in culture (TAA+miR-133a)
(n=4). * p < 0.05 vs control. # p<0.05 vs TAA.

Attenuation of thoracic aortic aneurysm by miR-133a replacement
Within the spectrum of cardiovascular diseases, TAAs are one of the most
dangerous and difficult to treat problems in cardiothoracic surgery. Aortic disease
in general, to which TAAs contribute, are a significant source of mortality for the
population, causing as many as 13,000 deaths annually in America, consistently
placing aortic disease among the top 20 causes of death (23-25). Further
understanding of the molecular mechanisms involved in TAA is essential and will
provide novel, less invasive therapeutic strategies.
Membrane-type 1 Matrix Metalloproteinase (MT1-MMP) has been
identified as a key mediator of TAA development due to the role in activation of
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other MMPs, ability to degrade all ECM components, and release/activation of
latent ECM-bound growth factors.(94, 188, 195, 321, 322) Furthermore, in an
earlier study performed by this laboratory, it was determined that MT1-MMP is
elevated in clinical and murine TAA tissue,(186, 188) and the development of
TAA was significantly attenuated in mice heterozygously deficient in MT1-MMP
(Figure 6.7). Therefore, MT1-MMP protein abundance was compared between
control and TAA fibroblasts and TAA fibroblasts with added exogenous miR-133a
by methods previously described. Results demonstrated that MT1-MMP protein
abundance was significantly increased in TAA fibroblasts, and addition of
exogenous miR-133a reduced MT1-MMP protein abundance in the TAA
fibroblasts (Figure 6.8). These results underscore that translational control
mechanisms, such as miR-133a, has an important role in modifying aortic
fibroblast MT1-MMP abundance.
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Figure 6.7 MT1-MMP is a key mediator in the development of TAA. Percent
change in thoracic aortic diameter of wild type mice, and mice heterozygously
deficient in MT1-MMP (MT1-MMP+/-) over time. * p<0.05 vs. baseline diameter
(Time 0). # p<0.05 vs wild type littermate. Unpublished data credited to Drs.
Jeffrey Jones and Rupak Mukerjee.
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Figure 6.8 Aortic fibroblast MT1-MMP protein abundance. The abundance of
MT1-MMP (IOD) determined by western blot using the antibody ab8221 in control,
TAA, and TAA fibroblasts treated with exogenous miR-133a (TAA+miR-133a)
(n=4). * p < 0.05 vs control. # p<0.05 vs TAA.

In agreement with the current results, this laboratory has previously
published, modulation of miR-133a by lentiviral transduction modulates MT1-MMP
protein abundance in myocardial fibroblasts.(243) With miR-133a overexpression
MT1-MMP is reduced, and with miR-133a knockdown by anti-miR-133a, MT1MMP is increased. To build upon this prior knowledge and preliminary results, a
bioinformatics approach was utilized to identify putative miR-133a target
sequences in genes known to be involved in TAA development. A TargetScan
Human analysis, which is a widely used predictor of microRNA targets, identified
a putative binding site in the MT1-MMP transcript and this sequence is conserved
across species (human, pig, and mouse; present in reverse orientation on 3’-DNA
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strand in mouse)(Figure 6.9). In addition, 5 other informatics algorithms
(specifically: MicroCosm Targets Version 5; DIANA; PITA;

Figure 6.9 Sequence alignment of putative miR-133a seed region.
Conservation of the miR-133a seed region in the MT1-MMP UTR transcripts of
human, pig, and mice.

RNA22; and RNAhybrid) identified miR-133a as a strong candidate for potential
interaction with the same seed region of the MT1-MMP transcript. To determine
whether MT1-MMP’s 3’UTR is a direct target of miR-133a, the 3’UTR of the human
MT1-MMP was cloned in line (3’ end) with the luciferase open reading frame in a
reporter plasmid. This allowed for the quantifiable determination of luminescence
dependent on whether miR-133a bound to the 3’ UTR sequence. In cells cotransfected with the MT1-MMP 3’ UTR and the miR-133a microRNA mimic,
luminescence was reduced to 47.9±3.4% of that of cells co-transfected with the
MT1-MMP 3’ UTR luciferase reporter plasmid and a non-targeting microRNA
mimic. Furthermore, no change in luminescence was observed in the vector
devoid of a 3’UTR (empty), GAPDH 3'UTR or random sequence 3’UTR controls
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co-transfected with either the miR-133a mimic or the non-targeting microRNA
mimic. These findings demonstrate that the MT1-MMP 3’UTR is a direct target of
miR-133a. (Figure 6.10).

Figure 6.10 MiR-133a targets the MT1-MMP 3’UTR. HT1080 cells were transfected with
luciferase reporter vector containing a vector void of a 3’UTR (Empty 3’UTR), the GAPDH
3’ UTR, a random sequence3’UTR, and the MT1-MMP 3’UTR. Reporter vectors were cotransfected with a miR-133a mimic or unrelated negative control micoRNA mimic. The
result of this assay was a reduction in luminescence observed in cells co-transfected with
the MT1-MMP 3’ UTR reporter GoClone plasmid and the miR-133a microRNA mimic, and
no change in luminescence was observed in cells co-transfected with the MT1-MMP 3’
UTR reporter GoClone plasmid and a non-targeting microRNA mimic. Furthermore, no
change in luminescence was observed in the empty, GAPDH or random sequence 3’UTR
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vector controls co-transfected with either the miR-133a mimic or the non-targeting
microRNA mimic.

The importance of miR-133a in the regulation of extracellular matrix
remodeling in cardiovascular tissue is becoming increasingly recognized. In
addition to miR-133a targeting the repression of a key protease directly involved
with the development of TAA, MT1-MMP, Carè et al. demonstrated in a murine
model of cardiac hypertrophy, that miR-133a is reduced in the hypertrophied
myocardium, and that in vivo knockdown of miR-133a (using anti-miR-133a)
induced cardiac hypertrophy.(216) Similarly, Torella et al. demonstrated miR133a was reduced in the carotid artery following balloon distension injury in a rat
model. Importantly, systemic overexpression of miR-133a by adenovirus,
attenuated post-injury remodeling, in contrast to miR-133a knockdown (using an
anti-miR-133a oligonucleotide) which worsened the response.(214) Data from
these studies emphasize the key role that miR-133a plays in cardiovascular
remodeling and suggest that the loss of miR-133a-mediated translational control
of targeted genes likely contributes to pathologic remodeling. Accordingly, a pilot
study was performed to explore whether viral-mediated miR-133a replacement
attenuates the development of TAA in calcium chloride induced murine model of
TAA.
In order to increase circulating levels of miR-133a, mice were injected
intravenously (by tail-vein injection) with a lentivirus that produces the murine
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miR-133a precursor. In this pilot study, TAA was induced in wild type FVB mice.
The following day, miR-133a lentivirus (1x109 pfu/100µl x1) was injected through
the tail-vein. The mice were survived for 25 days before terminal surgery with
blood and tissue harvest. Digital images were collected and aortic diameter was
measured at the time of TAA induction (baseline) and terminal surgery. Plasma
and aortic tissue levels of miR-133a were measured by QPCR, and MT1-MMP
protein abundance in the TAA tissue was measured by immunoblotting. Results
demonstrate increased plasma (Figure 6.11) and TAA tissue (Figure 6.12)
levels of miR-133a, and decreased tissue levels of MT1-MMP protein (Figure
6.13). Importantly, the increase in aortic diameter at 3 weeks post-TAA induction
was attenuated by treatment with miR-133a lentivirus (Figure 6.14). Using this
lentiviral delivery system, we will build on this pilot data through examination of
the effects of miR-133a on TAA development over time, following intravenous
treatment with miR-133a lentivirus or a lentivirus expressing a scrambled nontargeting miR sequence. Key preliminary studies for this aim provide proof of
feasibility of the described approach. Using this lentiviral delivery system and
incorporation of non-mammalian targeting lentivirus as a vehicle control, we will
increase our sample size to (n=10) as determined by power analysis (α=0.05,
β=0.20).
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Figure 6.11 Circulating plasma levels of miR-133a. Plasma miR-133a levels 3
weeks following a single tail vein injection of the miR-133a lentivirus (TAA+miR133a Lentivirus) (n=6) or the control saline (TAA)(n=4). An unpaired comparison
was made using a two sample t-test. * p < 0.05 vs TAA.
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Figure 6.12 Thoracic aortic tissue miR-133a abundance. Tissue miR-133a
abundance 3 weeks following a single tail vein injection of the miR-133a lentivirus
(TAA+miR-133a Lentivirus) (n=4) or the control saline (TAA) (n=3). An unpaired
comparison was made using a two sample t-test. * p < 0.05 vs TAA.

Figure 6.13 Thoracic aortic tissue MT1-MMP protein abundance. Tissue MT1MMP abundance 3 weeks following a single tail vein injection of the miR-133a
lentivirus (TAA+miR-133a Lentivirus) (n=6) or the control saline (TAA) (n=4). An
unpaired comparison was made using a two sample t-test. * p < 0.05 vs TAA.
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Figure 6.14 Aortic diameter measurements. Percent change in aortic diameter
from baseline measurements 3 weeks following the induction of TAA. Aortic
diameter was obtained by calibrated video microscopy 3 weeks following a single
tail vein injection of the miR-133a lentivirus (TAA+miR-133a Lentivirus) (n=4) or
the control saline (TAA) (n=6). An unpaired comparison was made using a two
sample t-test. * p < 0.05 vs TAA.
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Lentiviral transduction is not without limitations. Mammalian hosts have
evolved defense mechanisms against double-stranded RNA, typically present as
consequence of viral infection (interferon response). While these effects are not
commonly present following microRNA delivery, careful monitoring of such a
response will be maintained. An alternative approach is to utilize HDAC2
inhibition with Suberoylanilide hydroxamic acid (vorinostat), a United States-FDA
approved histone deacetylase inhibitor currently indicated and prescribed orally
for the treatment of patients with cutaneous T-cell lymphoma. Oral administration
of vorinostat has been demonstrated to increase cellular miR-133a levels in the
cardiovascular tissue of a mouse model of pressure overload induced cardiac
hypertrophy.(218)
While multiple approaches exist to increase cardiovascular tissue levels of
miR-133a, an additional aim of this study will be to inhibit the secretion of miR133a from the thoracic aorta, and determine the effects on the development of
TAA. As demonstrated in this body of work, tension reduces miR-133a in aortic
fibroblasts via exosome secretion, and the use of GW4869, the inhibitor of
nSMase2, prevents tension induced reduction of miR-133a. Most interestingly,
nSMase2 has been identified to be activated in response to acute changes in
vascular pressure.(323, 324) GW4869, which has been successfully delivered to
mice and rats in vivo (325, 326), will inhibit the secretion of exosomes at a
concentration of 20 uM (261, 280-282). Therefore, the use of an osmotic pump
will be employed to deliver GW4869 for 4 weeks following the induction of TAA.
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As an alternative method of nSMase2 inhibition, scyphostatin has been
demonstrated to inhibit mechano-induced nSMase activity in a dose-dependent
manner.(324) At the time of terminal surgery, aortic diameter will be obtained
and the abundance of miR-133a will be assessed in the plasma and descending
thoracic aorta. It is anticipated that inhibition of exosome secretion will lead to an
attenuation of TAA development, an increase in thoracic aortic tissue miR-133a,
and a decrease in circulating plasma miR-133a.
The significance from this body of work is through the identification that loss
of miR-133a alters cellular phenotype and plays an essential role in TAA formation.
Furthermore, a mechanism as to how miR-133a is reduced in thoracic aortic
fibroblasts has been identified. An important translational outcome from this set of
investigations is the identification of a specific molecular pathway responsible for
alterations that may mediate TAA development.

This will not only provide

foundational evidence for the mechanistic changes that occur in thoracic aortic
aneurysm formation, but may also have the potential to identify specific targets for
therapeutic intervention.
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CHAPTER 7: Methodology
The following section will describe in depth the methodology utilized for
the studies included in this body of work.
Ex vivo Thoracic Aortic Tension Application.
All animal care and surgical procedures were approved by the Medical
University of South Carolina Institutional Animal Care and Use Committee
(AR3380). Following induction of anesthesia with 2% isoflurane, wild type
C57BL/6 mice (10-16 weeks of age; Envigo) underwent thoracotomy and the
descending thoracic aorta was harvested. Endothelial-intact aortic tissue
segments were cut transversely into rings of approximately 3mm in length, which
were suspended on parallel wires, and bathed in an oxygenated physiologic salt
solution (Krebs-Henseleit solution) in an ex vivo tissue myograph. Aortic
segments were maintained at an experimentally derived optimal-tension
(normotension; 0.7g, ~70 mmHg equivalent) or elevated tension (1.5g, ~150
mmHg equivalent) utilizing methods previously described.(234, 235) Endothelialintact aortic segments were also held at 0.7g then treated with or without 100nm
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Angiotensin II (AngII) (A9525; Sigma) and allowed to contract against the parallel
wires; the peak tension generated was recorded. Following three hours of
applied tension or AngII exposure, aortic segments were homogenized in Trizol
and total RNA was extracted.
Cell Culture.
The descending thoracic aorta from wild-type C57BL/6 mice (10-16 weeks
of age; Envigo) was extracted and primary fibroblast cell lines were established
using an outgrowth technique as described previously.(320) The isolated thoracic
aortic fibroblasts were maintained in complete fibroblast-specific growth media
(Fibroblast growth media 2; C-23020, PromoCell) with added 10% Fetal Bovine
Serum (Gibco, Cat# 1600). Primary smooth muscle cell (SMC) lines were similarly
cultured from wild-type C57BL/6 mice (10-16 weeks of age; Envigo) using a similar
outgrowth procedure.(327) The isolated SMCs were maintained in SMC-specific
growth media with added supplement pack (SMC Growth Medium 2; C-22062,
PromoCell, Heidelberg Germany). All cell lines were treated with Amphotericin B
(5 ug/mL; A2942, Sigma) and Gentamicin (0.5 mg/mL; 15710-064, Gibco) during
the outgrowth phase only. All cell lines were maintained at 37oC in a water-jacketed
incubator, in a humidified 5% CO2/95% air atmosphere. Primary fibroblasts and
SMCs were utilized from passages 2-10.
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Primary cell biaxial cyclic tension application and Angiotensin II
stimulation.
Fibroblasts or smooth muscle cells were seeded at a density of 5,000 cells
per cm2 into amino coated Bioflex-6 well plates (BF-3001A; Flexcell International
Corporation, Burlington NC) and allowed to adhere overnight. Culture media was
then replaced with fresh complete media containing 10% exosome-depleted fetal
bovine serum (EXO-FBS; System Biosciences) with or without AngII (100nM,
A9525; Sigma). To inhibit exosome secretion, fibroblasts were pretreated with
the inhibitor of neutral sphingomyelinase, GW4869 (20nM for 24 hours)
(GW4869, Sigma, Cat# D1692). Following 24 hours, cells were rinsed with PBS
and appropriate culture media was replaced. Culture plates were held static
(control) or subjected to 12% biaxial cyclic stretch at a rate of 1Hz utilizing a
Flexcell culture system (FX5000, Flexcell International Corporation, Burlington,
NC).
QPCR.
Total RNA was extracted using TRIzol Reagent (Thermo Fisher Scientific,
Cat# 15596026), and quantified by NanoDrop 2000 (Thermo Fisher Scientific).
Samples were snap frozen in liquid nitrogen and stored at -80°C until use. For
cellular and tissue microRNA quantitation, single-stranded cDNA was synthesized
from 100 ng total RNA. Exosomal microRNA was quantified from exosomes
precipitated out of 5 ml of conditioned media (exposed to cells for 18 h). Circulating
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microRNA quantitation was achieved by total RNA isolation from 250uL of serum.
MicroRNA cDNA synthesis and PCR quantitation was performed using the miR133a-1-3p TaqMan microRNA Assay (Thermo Fisher, Cat# 002246-4427975)
according to the manufacturer’s instructions. Primary-microRNA expression was
determined by reverse transcription of 1 ug total RNA using the High Capacity
RNA-to-cDNA kit (Thermo Fisher Scientific, Cat# 4392339), followed by
quantitation using the ThermoFisher primary-microRNA analysis kit (pri-miR-133a1: Mm03306281_pri, and pri-miR-133a-2: Mm03307401_pri; Cat# 4427012). For
ribonuclease gene expression analysis, total RNA (1 μg) was reverse transcribed
with the iScript cDNA Synthesis Kit (170-8891, BioRad). Each cDNA was amplified
with gene-specific TaqMan expression assays (XRN1: Mm00496326_m1, XRN2:
Mm00457212_m1, ExoSC4: Mm00615045_g1, and GAPDH: Mm99999915_g1;
Applied Biosystems Cat# 4331182). QPCR reactions were performed on a BioRad CFX96 Real-Time System. All samples were tested in duplicate and
averaged. The relative expression of each mRNA and primary microRNA was
calculated and normalized to the internal control GAPDH using the comparative
cycle threshold (CT) method.(328) Relative expression intensity values were
calculated as 2-ΔCT, in which ΔCT are CT values normalized to the reference
control.
Immunoblot Analysis.
Relative abundance of XRN1, XRN2, ExoSC4, MT1-MMP and beta-Actin
were determined by immunoblotting. Briefly, 20 µg of each aortic fibroblast
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homogenate, determined by the Pierce BCA total protein assay (23225; Thermo
Fisher Scientific, City, State), was fractionated on a 4% to 12% bis-tris gradient
gel by electrophoresis. The proteins were transferred to nitrocellulose
membranes (0.45 µm; Bio-Rad, Hercules CA) and incubated in 5% nonfat dry
milk containing antisera specific for XRN1 (1ug/mL; Thermo Fisher Scientific,
PA5-41888), XRN2 (1:1,000; Thermo Fisher Scientific, PA5-38789), ExoSC4
(5ug/mL; Thermo Fisher Scientific, PA5-41890), MT1-MMP (1:10,000, ABcam,
AB8221), or beta-Actin (1:10,000; Biovision Inc., 3662-100). A secondary
peroxidase-conjugated antibody (primary antibody species-specific) was applied
(1:5000; 5% nonfat dry milk), and signals were detected with a chemiluminescent
substrate (Western Lighting Chemiluminescence Reagent Plus; PerkinElmer,
San Jose, CA) and recorded on film. Band intensity was quantified using Gel-Pro
Analyzer version 3.1.14 (Media Cybernetics, Silver Spring, MD).
Exosome Precipitation and Quantitation.
Fibroblasts were maintained in growth media containing 10% exosome
depleted FBS and exposed to 18 hours of 12% biaxial cyclic tension. Media was
collected and centrifuged at 3,000 x g for 15 minutes to remove cells and cell
debris. The supernatant was transferred to a separate tube and exosomes were
precipitated from the culture media (5 mL) using an exosome precipitation solution
(ExoQuick-TC, System Biosciences, Inc; Cat# EXOTC50A-1), following the
manufacturer’s instructions. Relative exosome abundance was compared using
acetylcholinesterase activity as a surrogate for exosome number using standard
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procedures.(275, 329) Briefly, the exosome fraction was suspended in 100uL of
phosphate buffered solution and incubated with 1.25 mM acetylthiocholine iodide
(Sigma, Cat# A5751) and 0.1 nM 5,5’-dithio-bis(2-nitrobenzoic acid) in a final
volume of 300 uL. The incubation was carried out at 37°C for 30 minutes, and the
change in absorbance was measured at 412nm on a Spectramax M3 (Molecular
Devices).
Murine Models of Hypertension.
Two distinct murine models of hypertension were employed. First, a
commercially available, hypertensive mouse (BPH2, Jackson Laboratories,
C57BL/6 background, Cat#003005) that initiates hypertension at 5 weeks of age
and peaks at 21 weeks. Low circulating levels of angiotensin-I have been
recorded in these animals suggesting that their hypertension is angiotensin-IIindependent.(14) The corresponding normotensive strain (BPN3, Jackson
Laboratories, C57BL/6 background, Cat# 003004) was used for control as well
as for the second hypertensive model consisting of the well-established
angiotensin-II (AngII) model of continuous infusion for 28 days (1.46 mg/kg/day).
Blood pressures were measured using a non-invasive tail-cuff system (CODA™,
Kent Scientific Corporation, Torrington, CT, USA).
Human Subjects.
Approval and inclusion criteria of human subjects were previously
defined.(330) Control patients fulfilled the general inclusion criteria, but did not
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have a history of hypertension. Hypertensive patients fulfilled the general
inclusion criteria and had a history of hypertension documented in their records
and/or had been told of this diagnosis by a physician, and were receiving
medication for its treatment. All hypertensive patients were diagnosed with left
ventricular hypertrophy. No patients included in this study had evidence of heart
failure as specified by the European Society of Cardiology and Heart Failure
Society of America criteria.(331, 332)
Murine Model of Thoracic Aortic Aneurysm
Anesthesia was induced in a closed chamber containing approximately 5%
isoflurane mixed with air. Following loss of consciousness each mouse was
weighed, and transferred to an ECG equipped feed-back temperature controlled
operating table (Indus Instruments, Houston, TX), with a modified mask
assembly delivering 2–3% isoflurane in oxygen. Buprenorphine (0.05-0.1 mg/kg
s.c.) was injected subcutaneously. A longitudinal incision (0.5cm) was made in
the anterior midline of the neck, to expose the trachea. An 18-gauge
angiocatheter was then advanced through the mouth into the trachea under
direct vision using a dissecting microscope (Zeiss Opmi 6, Carl Zeiss
MicroImaging, Inc., Thorwood, NY), and then connected to a rodent ventilator
(Hugo-Sachs) set at a respiratory rate of 250 breaths per min with a tidal volume
of 275 µl. The animal was then rotated to the right lateral decubitus position, and
a 1.0 cm lateral incision was made between the left side 4th and 5th intercostal
space. The muscle layers were divided sharply establishing access to the
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thoracic space. Baseline aortic dimensions were obtained by video microscopy
using a 3 megapixel color CCD camera (PAXcam3; MIS Inc., Villa Park, IL)
linked to a computer running PAX-it image management software with the live
measurement module (MIS, Inc., Villa Park, IL). Following baseline aortic
diameter measurements, a 3x1x8 mm sponge soaked in 0.5 M CaCl2 prepared in
normal saline was placed on the distal half of the exposed descending thoracic
aorta in direct contact with the periadventitial surface. After 15 min, the CaCl2soaked sponge was removed, and the thoracic cavity was irrigated liberally with
normal saline. Following lung re-expansion by obstructing the outflow on the
rodent ventilator for two breaths, the ribs were approximated with 7–0 suture.
The muscle layers were then closed, and the animal was rotated to the prone
position. Recovery was established using positive-pressure ventilation with 100%
oxygen, and, following extubation the animal was monitored for spontaneous
respiration then placed in a high oxygen content warmer for further recovery.
The day after TAA induction, the hsa-miR-133a lentiviral construct (CS970MR-1;
System Biosciences) (1x109 pfu in 100µl normal saline) was delivered via tail
vein injection.
Cellular Proliferation
Thoracic aortic fibroblasts were seeded at 1,000 cells per well of a 96 well
clear bottom plate (Costar Flat bottom Cell bind Surface [Poly-D-Lysine] Cat#
3300, Corning, NY), and allowed to adhere overnight. The following day growth
media was aspirated and replaced with fresh complete media. CyQuant Direct
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Cell Proliferation Assay (Cat#C35011, Molecular probes) kit was then used to
determine cell number. The basis of the CyQUANT kit is the use of a green
fluorescent dye, which exhibits strong fluorescence enhancement when bound to
cellular nucleic acids. This kit will be allowed to equilibrate to room temperature
and the following will be mixed: PBS (97.5%), Cyquant Direct nucleic acid stain
(0.004%), and direct background suppressor (0.02%). 12 hours following the
addition of fresh complete phenol-free fibroblast growth media, an equal volume
of 2X Detection reagent will be added to the cells in the culture media (assay is
compatible in media with or without serum). Cells were then incubated for 1 hour
at 37°C with 5% CO2. Following the one hour incubation time, fluorescence was
read from the bottom of the well at 480/535 Ex/Em. This was then repeated at
the denoted time points. For each cell line, a standard curve was generated by
preparation of a serial dilution of cell numbers ranging from 500 to 5,000. These
cells were allowed to adhere overnight, and then assayed directly by CyQUANT.
Fluorescence was then read from the bottom of the well at 480/535 Ex/Em.
Relative fluorescence correlates linearly with cell number.
Cellular Migration
A Boyden chamber assay was used to determine migration of thoracic
aortic fibroblasts. First, cellular proliferation was inhibited with the use of
mitomycin C (8 ug/mL, 1 hour; Sigma, M4287), then media was replaced with
fresh fibroblast growth media. The following day, cells were seeded (2.5x10 5
cells) into the upper chamber of the 8.0 µm pore polycarbonate membrane of the
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Transwell (Corning; Tewksbury, MA) chamber. The cells were allowed to adhere
overnight and then the media in the upper chamber was replaced with serum free
fibroblast growth media, with complete media being added to the lower chamber.
The cells were maintained under normal tissue culture conditions for 48 hours
and then fixed by immersion of the membranes in methanol at room temperature
for 30 minutes. The non-migrated cells on the top surface of the membrane were
removed with a cotton swab. Membranes were stained in 0.1% crystal violet in a
20% methanol solution for 30 minutes. Stained membranes were examined by
microscopy (10X) (Zeiss Axiovert 35). The number of cells which migrated
through the membrane were counted in five random fields and expressed as the
average number of cells per field of view.
MT1-MMP 3’UTR Target Confirmation
HT1080 cells, at a confluence of 70%, were co-transfected with
DharmaFECT-Duo transfection reagent and either the miR-133a mimic or a nonmRNA targeting control (10 nM) and 100 ng of one of the following vectors: the
empty 3’UTR vector, which contains only the luciferase gene and its constitutive
promoter and serves as the positive control; the GAPDH 3’UTR, which contains
the GAPDH 3’ UTR cloned downstream of the luciferase gene; the random
sequence 3’UTR, which contains non-conserved, non-genic and non-repetitive
human genomic fragments cloned downstream of the luciferase gene; or the
MT1-MMP 3’ UTR plasmid, which contains the human MT1-MMP (NM_004995)
3’UTR cloned downstream of the luciferase gene. Reporter assays were
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performed at 24 hours following transfection by the LightSwitch Luciferase Assay
system (LS010, SwitchGear Genomics). Luminescence was quantitated by
luminometer (VersaMax). All transfection experiments were performed four
times in triplicate.
Data analysis.
All data were assessed for normality. All statistical tests utilized in data
analysis for the determination of significance are listed in the corresponding
figure legends. Statistical tests were performed using STATA (Intercooled
STATA v8.2, College Station, TX). All data in figures were expressed as
absolute value, or fold change, as indicated in the figure legends. The
calculation of fold change was performed by setting the average of the control
values to 1, then applying the derived coefficient to the full data set. This
approach allows for sample variation to be assessed in both the control and
experimental groups. Data are represented as mean ± standard error of the
mean (SEM) in the text and figures. A p value of <0.05 was considered to be
statistically significant.
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